indexNCT04502056重复_由于各措施对应结局,nctid,outcome_description,participate_group_num,outcome_group_num,group_info,outcome_check,standard_outcome_check,checker_before,Time_Frame,conceptId,conceptName,domainId,outcome_id
1,NCT04452435,Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.),O1:45|O2:46,O1:0.19|O2:0.22,C21 Treatment|Placebo Treatment,C-reactive Protein (CRP),CRP,"['C-reactive Protein (CRP)', 'C-reactive Protein']",Time Frame: Day 1 through Day 29 ,4208414,C-reactive protein measurement,Measurement,outcome_1
2,NCT04452435,Change From Baseline in Body Temperature,O1:51|O2:54,O1:-0.11|O2:-0.34,C21 Treatment|Placebo Treatment,Body Temperature ,Body Temperature ,['Body Temperature'],Time Frame: Baseline ,4302666,Body temperature,Measurement,outcome_2
3,NCT04452435,Change From Baseline in IL-6,O1:31|O2:34,O1:0.73|O2:0.73,C21 Treatment|Placebo Treatment,IL-6 ,IL-6 ,['IL-6'],"Time Frame: Study period, up to two months from the day the first participant was screened ",4332015,IL-6 assay,Measurement,outcome_3
4,NCT04452435,Change From Baseline in IL-10,O1:37|O2:39,O1:0.66|O2:0.73,C21 Treatment|Placebo Treatment,IL-10 ,IL-10 ,['IL-10'],"Time Frame: Study period, up to two months from the day the first participant was screened ",4139809,Changed status,Observation,outcome_4
5,NCT04452435,Change From Baseline in TNF,O1:46|O2:46,O1:0.91|O2:1.01,C21 Treatment|Placebo Treatment,TNF,TNF,['TNF'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",35957205,TNF (tumor necrosis factor) gene variant measurement,Measurement,outcome_5
6,NCT04452435,Change From Baseline in CA125,O1:46|O2:48,O1:1.16|O2:1.17,C21 Treatment|Placebo Treatment,CA125,CA125,['CA125'],Time Frame: Baseline ,4139809,Changed status,Observation,outcome_6
7,NCT04452435,Change From Baseline in Ferritin,O1:46|O2:47,O1:0.75|O2:0.74,C21 Treatment|Placebo Treatment,Ferritin ,Ferritin ,['Ferritin'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",37397915,Serum ferritin level,Measurement,outcome_7
8,NCT04452435,Number of Subjects Not in Need of Oxygen Supply,O1:51|O2:55,O1:37|O2:30,C21 Treatment|Placebo Treatment,Need of Oxygen Supply ,Oxygen,"['Oxygen', 'Need of Oxygen Supply']",Time Frame: Up to 28 days ,4130549,Central oxygen supply,Device,outcome_8
9,NCT04452435,Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation,O1:51|O2:55,O1:50|O2:53,C21 Treatment|Placebo Treatment,Need of Mechanical Invasive or Non-invasive Ventilation ,Mechanical Ventilation,['Need of Mechanical Invasive or Non-invasive Ventilation'],Time Frame: Up to 28 days ,4177224,Noninvasive ventilation,Procedure,outcome_9
10,NCT04452435,Time to Need of Mechanical Invasive or Non-invasive Ventilation,O1:1|O2:2,O1:60.0|O2:77.925,C21 Treatment|Placebo Treatment,Time to Need of Mechanical Invasive or Non-invasive Ventilation ,Mechanical Ventilation,"['Time to Need of Mechanical Invasive or Non-invasive Ventilation', 'Need of Mechanical Invasive or Non-invasive Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",1035094,Non-invasive mechanical ventilator,Meas Value,outcome_10
11,NCT04452435,Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation),O1:51|O2:55,O1:5.0|O2:5.0,C21 Treatment|Placebo Treatment,Time on Oxygen Supply,Oxygen,"['Oxygen', 'Time on Oxygen Supply']",Time Frame: 5 and 14 days ,36308581,Supplemental oxygen,Meas Value,outcome_11
12,NCT04452435,Adverse Events,O1:51|O2:55,O1:31|O2:37,C21 Treatment|Placebo Treatment,Adverse Events ,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
13,NCT04452435,Oxygen Supplementation at Day 14,O1:51|O2:55,O1:1|O2:11,C21 Treatment|Placebo Treatment,Oxygen,Oxygen,['Oxygen'],NA,36308581,Supplemental oxygen,Meas Value,outcome_13
14,NCT04431908,"Sensitivity, Specificity and Accuracy",O1:1042,O1:889|O1:106|O1:27|O1:20,Outpatients (Drive Thru),"Sensitivity, Specificity and Accuracy ","Sensitivity, Specificity and Accuracy ","['Sensitivity, Specificity and Accuracy']",Time Frame: Baseline up to 60 days ,4148702,Sensitivity,Condition,outcome_14
15,NCT04431908,Repeatability,O1:0|O2:0,NA,Outpatients (Drive Thru)|High Risk Asymptomatics,Repeatability ,Repeatability ,['Repeatability'],"Time Frame: Baseline, Days 4, 7, 15, 21, and 29 ",4099902,Repeat,Observation,outcome_15
16,NCT04431908,"Asymptomatic Sensitivity, Specificity and Accuracy",O1:278,O1:244|O1:31|O1:27|O1:1,High Risk Asymptomatics,"Asymptomatic Sensitivity, Specificity and Accuracy ","Asymptomatic Sensitivity, Specificity and Accuracy ","['Asymptomatic Sensitivity, Specificity and Accuracy', 'Symptom', 'Sensitivity, Specificity and Accuracy']",Time Frame: At the first 5 days of study ,45881176,Asymptomatic,Meas Value,outcome_16
17,NCT04716426,COVID-19 Contamination Rate.,O1:50|O2:50,O1:2|O2:5,Tetracycline Hydrochloride 3%|Placebo,Contamination Rate,Contamination Rate,['Contamination Rate'],Time Frame: 12 days ,757681,COVID-19 case report,Measurement,outcome_17
18,NCT04716426,Number of Participants With Adverse Events,O1:50|O2:50,O1:17|O2:23,Tetracycline Hydrochloride 3%|Placebo,Adverse Events ,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
19,NCT04716426,Average Number of Adverse Events,O1:50|O2:50,O1:0.65|O2:0.94,Tetracycline Hydrochloride 3%|Placebo,Adverse Events ,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
20,NCT04716426,Days Over Which an Adverse Event Was Reported,O1:50|O2:50,O1:0.36|O2:0.28,Tetracycline Hydrochloride 3%|Placebo,Adverse Event,Adverse,"['Adverse', 'Adverse Event']",Time Frame: 24 hours ,45884383,Adverse event,Meas Value,outcome_18
21,NCT04716426,Other Virus or Bacteria Contamination Rate.,O1:50|O2:50,O1:0|O2:0,Tetracycline Hydrochloride 3%|Placebo,Virus or Bacteria Contamination Rate,Virus or Bacteria Contamination Rate,"['Virus or Bacteria Contamination Rate', 'Contamination Rate']",Time Frame: 0 to 24 hours post-dose ,42023572,Contamina,Geography,outcome_19
22,NCT04392141,Mortality Rate,O1:60|O2:60,O1:6|O2:1,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Mortality Rate ,Death ,"['Mortality Rate', 'Mortality']",Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
23,NCT04392141,SpO2,O1:60|O2:60,O1:87.39|O2:90.94|O1:92.89|O2:93.49,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,SpO2,SpO2,['SpO2'],Time Frame: Days 1 - 29. ,4096101,Measurement of oxygen saturation at periphery,Measurement,outcome_21
24,NCT04392141,Length of Hospitalization,O1:54|O2:59,O1:6.39|O2:4.17,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Hospitalization ,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 ,46236995,Hospital stay duration,Observation,outcome_22
25,NCT04392141,Lymphocyte Count,O1:60|O2:60,O1:1.19|O2:1.31|O1:1.17|O2:1.74,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Lymphocyte Count,Lymphocyte Count,['Lymphocyte Count'],"Time Frame: Baseline, Day 15, Day 29 ",37393858,Lymphocyte count,Measurement,outcome_23
26,NCT04392141,Serum Lactate Dehydrogenase,O1:60|O2:60,O1:664.98|O2:680.27|O1:691.04|O2:542.94,Standard Treatment|Colchicine and Herbal Phenolic Monoterpene Fractions,Serum Lactate Dehydrogenase ,Lactate Dehydrogenase,['Serum Lactate Dehydrogenase'],Time Frame: 28 days ,37392192,Serum lactate dehydrogenase level,Measurement,outcome_24
27,NCT04474496,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure,O1:117|O1:117|O1:117|O1:117|O1:117|O1:116|O1:117|O1:117|O1:117|O1:117|O1:117,O1:114|O1:112|O1:114|O1:109|O1:105|O1:113|O1:115|O1:113|O1:99|O1:114,Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.|Marshallese Adults in the U.S.,Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure ,Personal Preventative Behaviors ,['Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure'],Time Frame: 14 days ,3655973,At increased risk of exposure to Severe acute respiratory syndrome coronavirus 2,Condition,outcome_25
28,NCT04474496,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure,O1:120,O1:27|O1:23|O1:73|O1:41|O1:58|O1:59|O1:31|O1:61|O1:41|O1:47|O1:5|O1:3,Marshallese Adults in the U.S.,Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure ,Workplace Preventative,['Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure'],Time Frame: 0 to 24 hours post dose ,37311061|4061660,COVID-19|Preventive procedure,Condition|Procedure,outcome_26
29,NCT04474496,Effects of COVID-19 on General Health Status,O1:119,O1:20|O1:74|O1:19|O1:6,Marshallese Adults in the U.S.,Effects of COVID-19 on General Health Status ,General Health Status ,"['Effect', 'Effects of COVID-19 on General Health Status']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",37311061,COVID-19,Condition,outcome_27
30,NCT04474496,Effects of COVID-19 on Access to Healthcare Services,O1:120,O1:20|O1:14|O1:20|O1:21|O1:53|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Access to Healthcare Services ,Access to Healthcare Services ,"['Effect', 'Effects of COVID-19 on Access to Healthcare Services']",Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,37208126,Able to access healthcare services,Observation,outcome_28
31,NCT04474496,Effects of COVID-19 on Dietary Habits,O1:119,O1:25|O1:41|O1:30|O1:18|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Dietary Habits ,Dietary Habits ,"['Effects of COVID-19 on Dietary Habits', 'Effect']",Time Frame: Day 11 ,37311061,COVID-19,Condition,outcome_29
32,NCT04474496,Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise),O1:119,O1:27|O1:52|O1:35|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise) ,Physical Activity Behaviors,"['Effect', 'Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)']",Time Frame: 14 days ,46235931,Physical activity behavior,Observation,outcome_30
33,NCT04474496,Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise),O1:119,O1:17|O1:56|O1:37|O1:9,Marshallese Adults in the U.S.,Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise) ,Physical Activity Behaviors,"['Effect', 'Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)']","Time Frame: From start of mechanical ventilation until extubation or date of death from any cause, whichever came first, assessed up to 6 months ",46235931,Physical activity behavior,Observation,outcome_31
34,NCT04474496,Effects of COVID-19 on Weight,O1:119,O1:30|O1:26|O1:34|O1:26|O1:3,Marshallese Adults in the U.S.,Effects of COVID-19 on Weight ,Weight ,"['Effects of COVID-19 on Weight', 'Effect']",Time Frame: 0 to 24 hours post-dose ,37311061,COVID-19,Condition,outcome_32
35,NCT04474496,Effects of COVID-19 on HbA1c (Glycated Hemoglobin),O1:13,O1:2|O1:5|O1:3|O1:3,Marshallese Adults in the U.S.,HbA1c (Glycated Hemoglobin),HbA1c,"['Effect', 'Hemoglobin', 'HbA1c (Glycated Hemoglobin)']",NA,37116827,Glycated hemoglobin-A1c,Observation,outcome_33
36,NCT04474496,Barriers to Type 2 Diabetes Management Due to COVID-19,O1:13,O1:2|O1:1|O1:1|O1:3|O1:0|O1:9,Marshallese Adults in the U.S.,Barriers to Type 2 Diabetes Management Due to COVID-19 ,Type 2 Diabetes,['Barriers to Type 2 Diabetes Management Due to COVID-19'],Time Frame: Pre-SSI to 3-month follow-up ,37311061,COVID-19,Condition,outcome_34
37,NCT04474496,COVID-19 Screening,O1:120,O1:9|O1:7|O1:45|O1:32|O1:27|O1:28|O1:6,Marshallese Adults in the U.S.,COVID-19 Screening ,Screening ,['COVID-19 Screening'],Time Frame: Baseline to Day 28 ,37311061,COVID-19,Condition,outcome_35
38,NCT04474496,COVID-19 Testing,O1:120,O1:20|O1:1|O1:6|O1:54|O1:33|O1:9,Marshallese Adults in the U.S.,COVID-19 Testing ,Testing ,['COVID-19 Testing'],Time Frame: 14 days ,1333309,COVID-19 Related Testing,Observation,outcome_36
39,NCT04474496,COVID-19 Vaccine Willingness/Hesitancy,O1:113,O1:39|O1:25|O1:8|O1:9|O1:32,Marshallese Adults in the U.S.,COVID-19 Vaccine Willingness/Hesitancy ,Vaccine Willingness/Hesitancy,['COVID-19 Vaccine Willingness/Hesitancy'],"Time Frame: Pre-SSI, Immediately Post-SSI ",1310132,"When a COVID-19 vaccine is available to you, how likely are you to get vaccinated?",Observation,outcome_37
40,NCT04474496,Trusted Sources of COVID-19 Information,O1:117,O1:12|O1:15|O1:1|O1:14|O1:4|O1:40|O1:17|O1:7|O1:1|O1:1|O1:1|O1:4,Marshallese Adults in the U.S.,Trusted Sources of COVID-19 Information ,Trusted Sources,['Trusted Sources of COVID-19 Information'],Time Frame: Immediately Post-SSI only ,44789760,Sources of information,Observation,outcome_38
41,NCT04474496,Effects of COVID-19 on Housing,O1:118,O1:3|O1:12|O1:4|O1:98|O1:1,Marshallese Adults in the U.S.,Effects of COVID-19 on Housing ,Housing ,"['Effect', 'Effects of COVID-19 on Housing']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",37311061,COVID-19,Condition,outcome_39
42,NCT04474496,Effects of COVID-19 on Employment,O1:120,O1:12|O1:13|O1:9|O1:27|O1:4|O1:23|O1:4|O1:27|O1:5,Marshallese Adults in the U.S.,Effects of COVID-19 on Employment ,Employment ,"['Effect', 'Effects of COVID-19 on Employment']",Time Frame: Day 1 through Day 29 ,1617412,New employment during the COVID-19 outbreak,Observation,outcome_40
43,NCT04474496,Effects of COVID-19 on Income,O1:119,O1:3|O1:66|O1:43|O1:7,Marshallese Adults in the U.S.,Effects of COVID-19 on Income ,Income ,"['Effect', 'Effects of COVID-19 on Income']",Time Frame: Day 12 ,37311061,COVID-19,Condition,outcome_41
44,NCT04474496,Sources of Stress During COVID-19,O1:120,O1:75|O1:90|O1:75|O1:79|O1:61|O1:75|O1:59|O1:24|O1:43|O1:32|O1:27|O1:47|O1:5|O1:1|O1:2,Marshallese Adults in the U.S.,Sources of Stress During COVID-19 ,Sources of Stress,['Sources of Stress During COVID-19'],"Time Frame: Day 1 (Baseline), Day 15 ",37311061,COVID-19,Condition,outcome_42
45,NCT04646109,Gender Distribution of the Patients,O1:30|O2:30,O1:19|O2:21|O1:11|O2:9,Control Group|Study Group,Gender,Gender,['Gender'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4077869,Distribution pattern,Observation,outcome_43
46,NCT04646109,Age Distribution of the Patients,O1:30|O2:30,O1:66.23|O2:58.17,Control Group|Study Group,Age Distribution,Age Distribution,['Age Distribution'],Time Frame: At the first day of the study ,4265453,Age,Observation,outcome_44
47,NCT04646109,Percentage of Patients With Accompanying Diseases,O1:30|O2:30,O1:10|O2:9|O1:12|O2:15|O1:8|O2:5|O1:1|O2:0|O1:3|O2:6|O1:1|O2:0|O1:1|O2:0,Control Group|Study Group,Accompanying Diseases ,Accompanying Diseases ,['Accompanying Diseases'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,433128,Complication,Condition,outcome_45
48,NCT04646109,Percentage of Patients With Baseline Clinical Symptoms,O1:30|O2:30,O1:13|O2:15|O1:14|O2:16|O1:1|O2:3|O1:19|O2:23|O1:2|O2:5|O1:11|O2:13|O1:7|O2:9|O1:0|O2:1|O1:0|O2:1,Control Group|Study Group,Clinical Symptoms ,Symptoms,"['Symptom', 'Clinical Symptoms']",Time Frame: Baseline ,46234710,Symptom,Observation,outcome_46
49,NCT04646109,Body Temperature Means of the Patients,O1:30|O2:30,O1:36.8|O2:36.9,Control Group|Study Group,Body Temperature,Body Temperature,['Body Temperature'],Time Frame: Baseline ,4302666,Body temperature,Measurement,outcome_47
50,NCT04646109,Heart Rate Means of the Patients,O1:30|O2:30,O1:92|O2:88,Control Group|Study Group,Heart Rate,Heart Rate,['Heart Rate'],Time Frame: Day 1 through Day 29 ,40769110,Heart rate 10 minutes mean [palpation],Measurement,outcome_48
51,NCT04646109,Respiratory Rate Means of the Patients,O1:30|O2:30,O1:24.7|O2:24,Control Group|Study Group,Respiratory Rate,Respiratory Rate,['Respiratory Rate'],Time Frame: Baseline to Day 29 ,4300739,Respiratory rate measurement assessment,Procedure,outcome_49
52,NCT04646109,Systolic and Diastolic Pressure Means of the Patients,O1:30|O2:30,O1:124.61|O2:124.39|O1:73.43|O2:75.64,Control Group|Study Group,Systolic and Diastolic Pressure,Blood Pressure,['Systolic and Diastolic Pressure'],Time Frame: 14 days ,40758413,Blood pressure systolic and diastolic,Measurement,outcome_50
53,NCT04646109,Number of Participants With Clinical Response,O1:30|O2:30,O1:11|O2:14,Control Group|Study Group,Clinical Response ,Clinical Response,['Clinical Response'],Time Frame: Baseline ,4323504,Clinical trial participant,Observation,outcome_51
54,NCT04646109,Changes in Oxygen Saturation (SpO2) Values,O1:30|O2:30,O1:89.67|O2:89.93|O1:90.50|O2:92.85|O1:91.90|O2:93.07|O1:93.00|O2:93.52,Control Group|Study Group,Oxygen Saturation (SpO2),SpO2,"['Oxygen', 'SpO2', 'Oxygen Saturation (SpO2)', 'Oxygen Saturation']",Time Frame: 28 days after randomization ,4196147,Peripheral oxygen saturation,Measurement,outcome_52
55,NCT04646109,Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2),O1:30|O2:30,O1:197.44|O2:158.83|O1:181.83|O2:147.31|O1:174.77|O2:147.74|O1:180.13|O2:178.94,Control Group|Study Group,PaO2/FiO2,P/F Ratio,"['Oxygen', 'PaO2/FiO2']",Time Frame: 28 days after randomization ,4353936,Inspired oxygen concentration,Measurement,outcome_53
56,NCT04646109,Changes in Serum Lymphocyte Counts,O1:30|O2:30,O1:1010|O2:932|O1:1034|O2:928|O1:977|O2:1021|O1:968|O2:1273,Control Group|Study Group,Serum Lymphocyte Counts,Lymphocyte,"['Serum Lymphocyte Counts', 'Lymphocyte Count']",Time Frame: 28 days ,37393858,Lymphocyte count,Measurement,outcome_54
57,NCT04646109,Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L),O1:30|O2:30,O1:7.48|O2:8.77|O1:7.74|O2:10.82|O1:9.26|O2:9.02|O1:9.88|O2:7.16,Control Group|Study Group,PNL/L,PNL/L,"['PNL/L', 'Lymphocyte Count']",Time Frame: Anytime during pregnancy or within 6 months after given birth. ,4024539,Polymorphonuclear leukocyte count,Measurement,outcome_55
58,NCT04646109,Changes in Serum Ferritin Levels,O1:30|O2:30,O1:747.05|O2:682.75|O1:783.03|O2:834.94|O1:881.17|O2:875.90|O1:1028.24|O2:875.12,Control Group|Study Group,Serum Ferritin Levels ,Ferritin,"['Serum Ferritin Levels', 'Ferritin']",Time Frame: Baseline up to 60 days ,37397915,Serum ferritin level,Measurement,outcome_56
59,NCT04646109,Changes in Serum D-dimer Levels,O1:30|O2:30,O1:1.32|O2:1.25|O1:2.80|O2:1.40|O1:4.14|O2:3.24|O1:3.58|O2:5.85,Control Group|Study Group,Serum D-dimer Levels ,D-dimer,"['Serum D-dimer Levels', 'D-dimer']",Time Frame: Baseline up to 60 days ,37393605,D-dimer level,Measurement,outcome_57
60,NCT04646109,Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism,O1:0|O2:36,O1:0|O2:6|O1:0|O2:30,Control Group|Study Group,Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism ,Genetic Examination,['Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism'],Time Frame: Day 1 through Day 29 ,4237017,Genetic test,Measurement,outcome_58
61,NCT04646109,Treatment-Related Adverse Events as Assessed by CTCAE v4.0,O1:30|O2:30,O1:2|O2:0|O1:1|O2:0,Control Group|Study Group,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 48 hours ,763788,National Cancer Institute common terminology criteria for adverse events,Measurement,outcome_59
62,NCT04646109,Mortality,O1:30|O2:30,O1:9|O2:6,Control Group|Study Group,Mortality ,Death ,['Mortality'],Time Frame: Baseline ,4249566,Mortality rate,Observation,outcome_60
63,NCT04646109,Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity,O1:8|O2:16,O1:3|O2:14,Control Group|Study Group,Polymerase Chain Reaction (PCR),PCR,['Polymerase Chain Reaction (PCR)'],Time Frame: Up to and including day 7 ,3667069,Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction,Observation,outcome_61
64,NCT04542694,Rate of Clinical Status Improvement,O1:100|O2:100,O1:27|O2:15,Favipiravir (Areplivir)|Standard of Care,Improvement,Improvement,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: 28 days ,4308350,Improvement of status,Observation,outcome_62
65,NCT04542694,Time to Clinical Improvement,O1:100|O2:100,O1:8|O2:12,Favipiravir (Areplivir)|Standard of Care,Improvement,Improvement,"['improvement', 'Improvement']",Time Frame: 28 days ,4138597,Clinical status,Observation,outcome_63
66,NCT04542694,Rate of Viral Elimination by Day 10,O1:100|O2:100,O1:98|O2:79,Favipiravir (Areplivir)|Standard of Care,Viral Elimination,Viral Clearance,['Viral Elimination'],Time Frame: Pre-SSI only ,4271038,Excretory function,Observation,outcome_64
67,NCT04542694,Time Before the End of Fever,O1:100|O2:100,O1:4|O2:5,Favipiravir (Areplivir)|Standard of Care,Fever ,Fever ,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",21495022,Fever duration,Observation,outcome_65
68,NCT04542694,Change in the Level of Lung Damage According to CT,O1:100|O2:100,O1:60|O2:40,Favipiravir (Areplivir)|Standard of Care,Lung Damage,Lung Damage,['Lung Damage'],"Time Frame: Baseline, Day 15, Day 29 ",45884896,Lung Disease,Meas Value,outcome_66
69,NCT04542694,Rate of Transfer to the Intensive Care Unit,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Intensive Care,Intensive Care,['Intensive Care'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) ",4265599,Patient transfer to intensive care unit,Observation,outcome_67
70,NCT04542694,Rate of the Use of Non-invasive Lung Ventilation,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Non-invasive Lung Ventilation ,Non-invasive Lung Ventilation ,['Non-invasive Lung Ventilation'],Time Frame: One-month ,4177224,Noninvasive ventilation,Procedure,outcome_68
71,NCT04542694,Rate of the Use of Mechanical Ventilation,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Mechanical Ventilation ,Mechanical Ventilation ,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",4230167,Artificial respiration,Procedure,outcome_69
72,NCT04542694,Mortality,O1:100|O2:100,O1:0|O2:0,Favipiravir (Areplivir)|Standard of Care,Mortality,Death ,['Mortality'],Time Frame: within 14 days after enrollement ,4249566,Mortality rate,Observation,outcome_70
73,NCT04401579,Time to Recovery,O1:515|O2:518,O1:7.0|O2:8.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Recovery,Recovery,"['Recovery', 'Time to Recovery']","Time Frame: Day 14, Chronic Phase ",31999,Recovered,Cost,outcome_71
74,NCT04401579,Change From Baseline in Alanine Transaminase (ALT),O1:491|O2:491|O1:491|O2:491|O1:407|O2:406|O1:268|O2:284|O1:187|O2:201|O1:250|O2:270|O1:256|O2:255,O1:3.3|O2:2.0|O1:16.8|O2:8.8|O1:7.9|O2:7.8|O1:0.0|O2:7.3|O1:5.0|O2:3.9|O1:-5.4|O2:2.3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Alanine Transaminase (ALT),ALT,['Alanine Transaminase (ALT)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) ,4095055,ALT - blood measurement,Measurement,outcome_72
75,NCT04401579,Change From Baseline in Aspartate Transaminase (AST),O1:486|O2:487|O1:486|O2:487|O1:404|O2:403|O1:265|O2:282|O1:185|O2:200|O1:246|O2:266|O1:251|O2:251,O1:3.1|O2:2.4|O1:27.4|O2:2.8|O1:-5.6|O2:-4.3|O1:-10.6|O2:6.4|O1:-6.0|O2:-3.9|O1:-17.1|O2:2.4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Aspartate Transaminase (AST),AST,['Aspartate Transaminase (AST)'],Time Frame: At the first day of ivermectin therapy (1st day) ,4189605,Aspartate transaminase level,Condition,outcome_73
76,NCT04401579,Change From Baseline in Creatinine,O1:494|O2:495|O1:494|O2:495|O1:412|O2:410|O1:270|O2:285|O1:190|O2:202|O1:254|O2:273|O1:260|O2:257,O1:-0.036|O2:-0.019|O1:-0.078|O2:0.001|O1:-0.082|O2:0.129|O1:-0.055|O2:0.194|O1:-0.042|O2:0.094|O1:-0.034|O2:0.033,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Creatinine,Creatinine,['Creatinine'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",42593557,Urine creatinine increased,Condition,outcome_74
77,NCT04401579,Change From Baseline in Glucose,O1:493|O2:493|O1:493|O2:493|O1:412|O2:409|O1:270|O2:284|O1:190|O2:203|O1:252|O2:271|O1:257|O2:256,O1:-17.1|O2:-6.0|O1:-15.9|O2:-1.6|O1:-16.8|O2:5.0|O1:-8.1|O2:1.2|O1:-11.1|O2:0.8|O1:-4.6|O2:-2.2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Glucose,Glucose,['Glucose'],Time Frame: Day 1 through Day 29 ,45770408,Baseline blood glucose concentration,Measurement,outcome_75
78,NCT04401579,Change From Baseline in Hemoglobin,O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:270|O2:284|O1:189|O2:199|O1:253|O2:267|O1:260|O2:254,O1:-0.46|O2:-0.34|O1:-0.62|O2:-0.64|O1:-0.93|O2:-1.08|O1:-1.29|O2:-1.62|O1:-0.96|O2:-1.12|O1:-0.54|O2:-0.77,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Hemoglobin,Hemoglobin,['Hemoglobin'],Time Frame: Day 1 through Day 29 ,4289753,Hemoglobin H,Observation,outcome_76
79,NCT04401579,Change From Baseline in Platelets,O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:269|O2:284|O1:189|O2:199|O1:252|O2:267|O1:260|O2:254,O1:55.9|O2:52.6|O1:116.6|O2:106.1|O1:197.9|O2:158.9|O1:229.9|O2:145.7|O1:175.9|O2:111.6|O1:16.5|O2:36.9,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Platelets,Platelet,"['Platelets', 'Platelet']",Time Frame: 28 and 90 day evaluation ,36879118,human platelets,Drug,outcome_77
80,NCT04401579,Change From Baseline in Prothrombin International Normalized Ratio (INR),O1:447|O2:439|O1:447|O2:439|O1:360|O2:370|O1:244|O2:250|O1:162|O2:175|O1:222|O2:241|O1:232|O2:232,O1:-0.03|O2:0.05|O1:0.02|O2:0.08|O1:0.01|O2:0.08|O1:0.04|O2:0.03|O1:-0.04|O2:-0.08|O1:-0.12|O2:-0.03,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Prothrombin International Normalized Ratio (INR),INR,['Prothrombin International Normalized Ratio (INR)'],Time Frame: 24 hours after a 1000 U intranasal dose of heparin ,35917345,International Normalized Ratio for Prothrombin Time (INR),Measurement,outcome_78
81,NCT04401579,Change From Baseline in Total Bilirubin,O1:490|O2:491|O1:490|O2:491|O1:407|O2:405|O1:268|O2:284|O1:187|O2:201|O1:250|O2:270|O1:256|O2:254,O1:-0.06|O2:-0.01|O1:-0.04|O2:0.01|O1:-0.06|O2:0.01|O1:-0.08|O2:0.08|O1:-0.10|O2:0.08|O1:-0.10|O2:0.01,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Total Bilirubin,Total Bilirubin,['Total Bilirubin'],Time Frame: Pre-SSI to Immediately Post-SSI; Pre-SSI to 3-month follow-up ,4230543,"Bilirubin, total measurement",Measurement,outcome_79
82,NCT04401579,Change From Baseline in White Blood Cell Count (WBC),O1:493|O2:494|O1:493|O2:494|O1:410|O2:409|O1:270|O2:284|O1:189|O2:199|O1:253|O2:267|O1:260|O2:254,O1:-0.831|O2:-0.037|O1:-0.276|O2:0.392|O1:0.663|O2:1.606|O1:1.869|O2:2.938|O1:0.694|O2:2.162|O1:-0.364|O2:0.712,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,White Blood Cell Count (WBC),WBC,['White Blood Cell Count (WBC)'],Time Frame: 0 to 24 hours post dose ,4298431,White blood cell count,Measurement,outcome_80
83,NCT04401579,Change From Baseline in Neutrophils,O1:488|O2:493|O1:488|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:-1.925|O2:-0.333|O1:-1.334|O2:-0.204|O1:-0.813|O2:1.139|O1:-0.046|O2:1.847|O1:-1.192|O2:1.414|O1:-1.708|O2:-0.656,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Neutrophils,Neutrophils,['Neutrophils'],Time Frame: Day 28 ,42596538,Toxic change in neutrophil,Condition,outcome_81
84,NCT04401579,Change From Baseline in Lymphocytes,O1:488|O2:493|O1:488|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:0.503|O2:0.074|O1:0.620|O2:0.205|O1:0.515|O2:0.304|O1:0.541|O2:0.409|O1:0.687|O2:0.718|O1:0.653|O2:0.927,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Lymphocytes,Lymphocytes,['Lymphocytes'],"Time Frame: Baseline, Day 15, Day 29 ",36309122,Lymphocytes,Meas Value,outcome_82
85,NCT04401579,Change From Baseline in Monocytes,O1:487|O2:493|O1:487|O2:493|O1:408|O2:404|O1:268|O2:282|O1:186|O2:196|O1:249|O2:267|O1:257|O2:253,O1:0.004|O2:0.062|O1:0.094|O2:0.153|O1:0.105|O2:0.279|O1:0.210|O2:0.378|O1:0.256|O2:0.329|O1:0.108|O2:0.212,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Monocytes,Monocytes,['Monocytes'],Time Frame: 14 days ,36310669,Monocytes,Meas Value,outcome_83
86,NCT04401579,Change From Baseline in Basophils,O1:483|O2:492|O1:483|O2:492|O1:402|O2:402|O1:265|O2:281|O1:185|O2:195|O1:247|O2:265|O1:257|O2:250,O1:0.000|O2:0.001|O1:0.007|O2:0.006|O1:0.011|O2:0.017|O1:0.014|O2:0.022|O1:0.026|O2:0.037|O1:0.022|O2:0.036,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Basophils,Basophils,['Basophils'],Time Frame: From 6th to the end of 10th day ,4099772,Basophilic degeneration,Observation,outcome_84
87,NCT04401579,Change From Baseline in Eosinophils,O1:484|O2:492|O1:484|O2:492|O1:405|O2:403|O1:265|O2:281|O1:185|O2:195|O1:247|O2:264|O1:257|O2:251,O1:0.050|O2:0.039|O1:0.104|O2:0.075|O1:0.088|O2:0.086|O1:0.078|O2:0.115|O1:0.121|O2:0.109|O1:0.192|O2:0.205,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Eosinophils,Eosinophils,['Eosinophils'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",45884164,Eosinophils,Meas Value,outcome_85
88,NCT04401579,Change in National Early Warning Score (NEWS) From Baseline,O1:515|O2:518,O1:-0.5|O2:-0.1|O1:-0.9|O2:-0.4|O1:-1.5|O2:-0.8|O1:-1.8|O2:-1.1|O1:-2.1|O2:-1.2|O1:-2.0|O2:-1.2|O1:-2.2|O2:-1.4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,National Early Warning Score (NEWS) ,NEWS,['National Early Warning Score (NEWS)'],Time Frame: Up to 28 days ,44808684,Royal College of Physicians NEWS (national early warning score),Measurement,outcome_86
89,NCT04401579,Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs),O1:507|O2:509,O1:40.8|O2:46.8,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. ,45884383,Adverse event,Meas Value,outcome_87
90,NCT04401579,Percentage of Participants Reporting Serious Adverse Events (SAEs),O1:507|O2:509,O1:16.0|O2:21.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. ,4158959,Serious reportable event,Observation,outcome_88
91,NCT04401579,Duration of Hospitalization,O1:515|O2:518|O1:515|O2:518|O1:491|O2:481,O1:8|O2:8|O1:8|O2:8,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 11 ,46236995,Hospital stay duration,Observation,outcome_89
92,NCT04401579,Duration of New Non-invasive Ventilation or High Flow Oxygen Use,O1:70|O2:82|O1:70|O2:82|O1:65|O2:72,O1:6|O2:4.5|O1:5|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Non-invasive Ventilation or High Flow Oxygen Use,Oxygen,"['Oxygen', 'New Non-invasive Ventilation or High Flow Oxygen Use', 'Oxygen Use']",Time Frame: Day 28 ,4177224,Noninvasive ventilation,Procedure,outcome_90
93,NCT04401579,Duration of New Oxygen Use,O1:16|O2:29,O1:3|O2:3|O1:3|O2:3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Oxygen Use,Oxygen,"['Oxygen', 'New Oxygen Use', 'Oxygen Use']","Time Frame: Day 0, Day 3, Day 5, and Day 7 ",40493512,Oxygen saturation below reference range,Condition,outcome_91
94,NCT04401579,Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:46|O2:70|O1:46|O2:70|O1:39|O2:52,O1:16|O2:27|O1:13|O2:20,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,"['Oxygen', 'ECMO', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: after each inhalation during 10 days ,4052536,Extracorporeal membrane oxygenation,Procedure,outcome_92
95,NCT04401579,Duration of Oxygen Use,O1:445|O2:446|O1:445|O2:446|O1:421|O2:409,O1:10|O2:12|O1:9|O2:10,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Oxygen Use,Oxygen,"['Oxygen', 'Oxygen Use']",Time Frame: 28 days after randomization ,40486533,Finding of oxygen saturation,Condition,outcome_93
96,NCT04401579,Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics,O1:515|O2:518,O1:55|O2:51|O1:0|O2:1|O1:66|O2:59|O1:0|O2:1|O1:2|O2:2|O1:16|O2:18|O1:23|O2:27|O1:30|O2:34|O1:3|O2:4|O1:4|O2:5,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Discontinued or Temporarily Suspended From Investigational Therapeutics,Discontinued,"['Discontinued or Temporarily Suspended From Investigational Therapeutics', 'Discontinued']",Time Frame: Day 1 through Day 29 ,4133895|36309075,Therapeutic|Discontinue,Observation|Meas Value,outcome_94
97,NCT04401579,Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:461|O2:461,O1:10|O2:15,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,"['Oxygen', 'ECMO', 'Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']","Time Frame: from first inhalation until discharge from the clinic, up to 30 days ",4052536,Extracorporeal membrane oxygenation,Procedure,outcome_95
98,NCT04401579,Percentage of Participants Requiring New Oxygen Use,O1:70|O2:72,O1:23|O2:40,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,New Oxygen Use,Oxygen,"['Oxygen', 'New Oxygen Use', 'Participants Requiring New Oxygen Use', 'Oxygen Use']","Time Frame: Day 0, Day 3, Day 5, and Day 7 ",40482644,Oxygen percentage delivered,Observation,outcome_96
99,NCT04401579,Mean Change in the Ordinal Scale,O1:515|O2:518,O1:0.1|O2:0.1|O1:0.0|O2:0.0|O1:-0.3|O2:-0.1|O1:-0.4|O2:-0.2|O1:-2.3|O2:-1.9|O1:-2.7|O2:-2.3|O1:-2.9|O2:-2.5,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Mean Change', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 ",4062806,Scale,Device,outcome_97
100,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15,O1:515|O2:518,O1:2|O2:3|O1:9|O2:16|O1:4|O2:4|O1:8|O2:10|O1:6|O2:3|O1:2|O2:1|O1:34|O2:31|O1:34|O2:32,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 ",4138597,Clinical status,Observation,outcome_98
101,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1,O1:515|O2:518,O1:0|O2:0|O1:10|O2:11|O1:20|O2:22|O1:56|O2:53|O1:14|O2:14|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: day 7, day 14 ,day 21 & day 30 ",4138597,Clinical status,Observation,outcome_99
102,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3,O1:515|O2:518,O1:0.4|O2:0|O1:15|O2:16|O1:22|O2:22|O1:45|O2:44|O1:16|O2:14|O1:0.2|O2:1|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0.2|O2:0.4|O1:1|O2:2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Pre and Post 1st dose; Pre and Post 2nd dose ,4138597,Clinical status,Observation,outcome_100
103,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5,O1:515|O2:518,O1:1|O2:0|O1:15|O2:18|O1:17|O2:18|O1:35|O2:33|O1:19|O2:15|O1:1|O2:1|O1:0.2|O2:0|O1:0.2|O2:0|O1:0|O2:0.2|O1:10|O2:13|O1:2|O2:3,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Baseline, Day 7, Day 14, Day 21 & Day 30 ",4138597,Clinical status,Observation,outcome_101
104,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8,O1:515|O2:518,O1:1|O2:1|O1:13|O2:18|O1:11|O2:12|O1:18|O2:18|O1:12|O2:10|O1:1|O2:1|O1:0.2|O2:0|O1:0.4|O2:0|O1:0|O2:0.4|O1:40|O2:36|O1:3|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: up to Day 30 ,4138597,Clinical status,Observation,outcome_102
105,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11,O1:515|O2:518,O1:1|O2:2|O1:11|O2:16|O1:6|O2:7|O1:12|O2:10|O1:9|O2:7|O1:1|O2:1|O1:0|O2:0|O1:0.2|O2:0.2|O1:0|O2:1|O1:56|O2:52|O1:3|O2:4,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Up to day 14 ,4138597,Clinical status,Observation,outcome_103
106,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22,O1:515|O2:518,O1:4|O2:6|O1:6|O2:9|O1:3|O2:1|O1:3|O2:5|O1:2|O2:3|O1:1|O2:0.4|O1:24|O2:25|O1:44|O2:37|O1:0|O2:0|O1:4|O2:3|O1:9|O2:10,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Up to day 28 ,4138597,Clinical status,Observation,outcome_104
107,NCT04401579,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29,O1:515|O2:518,O1:5|O2:7|O1:3|O2:7|O1:2|O2:1|O1:2|O2:3|O1:3|O2:1|O1:1|O2:0.2|O1:23|O2:23|O1:49|O2:43|O1:0|O2:0|O1:0.4|O2:1|O1:12|O2:13|O1:0.2|O2:0.2,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: 14 days ,4138597,Clinical status,Observation,outcome_105
108,NCT04401579,14-day Participant Mortality,O1:515|O2:518,O1:0.02|O2:0.03,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Mortality,Death ,['Mortality'],Time Frame: 28 days ,4249566,Mortality rate,Observation,outcome_106
109,NCT04401579,28-day Participant Mortality,O1:515|O2:518,O1:0.05|O2:0.08,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Mortality,Death ,['Mortality'],Time Frame: within 14 days after enrollement ,4249566,Mortality rate,Observation,outcome_70
110,NCT04401579,Time to an Improvement of One Category Using an Ordinal Scale,O1:515|O2:518,O1:6.0|O2:8.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days ,4308350,Improvement of status,Observation,outcome_107
111,NCT04401579,Time to an Improvement of Two Categories Using an Ordinal Scale,O1:515|O2:518,O1:12.0|O2:13.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days ,35621943,Patient Global Impression of Improvement,Measurement,outcome_108
112,NCT04401579,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First",O1:361|O2:334,O1:6.0|O2:7.0,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,Discharge,Discharge,"['discharge', 'Discharge']",Time Frame: Day 22 ,46235136,Discharge time,Observation,outcome_109
113,NCT04401579,Change From Baseline in C-reactive Protein (CRP),O1:446|O2:455|O1:446|O2:455|O1:368|O2:367|O1:241|O2:250|O1:159|O2:181|O1:221|O2:240|O1:217|O2:219,O1:-23.035|O2:-18.671|O1:-58.935|O2:-30.908|O1:-78.411|O2:-62.038|O1:-103.789|O2:-88.881|O1:-122.339|O2:-112.588|O1:-131.333|O2:-122.342,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,C-reactive Protein (CRP),CRP,"['C-reactive Protein (CRP)', 'C-reactive Protein']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4208414,C-reactive protein measurement,Measurement,outcome_110
114,NCT04401579,Change From Baseline in D-dimer Concentration,O1:436|O2:432|O1:436|O2:432|O1:352|O2:347|O1:227|O2:230|O1:153|O2:160|O1:215|O2:230|O1:223|O2:206,O1:-0.374|O2:0.384|O1:0.053|O2:-0.149|O1:-0.271|O2:0.351|O1:0.622|O2:0.309|O1:-0.988|O2:-0.422|O1:0.774|O2:-0.219,Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo|Remdesivir Plus Baricitinib|Remdesivir Plus Placebo,D-dimer Concentration,D-dimer,"['D-dimer', 'D-dimer Concentration']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",37392968,Plasma D-dimer concentration,Measurement,outcome_111
115,NCT04280705,Time to Recovery,O1:521|O2:541,O1:15|O2:10,Placebo|Remdesivir,Time to Recovery ,Recovery,"['Recovery', 'Time to Recovery']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",31999,Recovered,Cost,outcome_112
116,NCT04280705,Change From Baseline in Alanine Transaminase (ALT),O1:463|O2:465|O1:463|O2:465|O1:403|O2:398|O1:327|O2:296|O1:257|O2:227|O1:242|O2:257|O1:180|O2:220,O1:14.3|O2:2.9|O1:23.1|O2:10.8|O1:24.2|O2:8.9|O1:27.7|O2:3.4|O1:28.1|O2:1.7|O1:-3.9|O2:-6.8,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Alanine Transaminase (ALT),ALT,['Alanine Transaminase (ALT)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) ,4095055,ALT - blood measurement,Measurement,outcome_72
117,NCT04280705,Change From Baseline in Aspartate Transaminase (AST),O1:438|O2:445|O1:438|O2:445|O1:384|O2:380|O1:315|O2:285|O1:247|O2:219|O1:236|O2:248|O1:170|O2:208,O1:13.7|O2:-2.0|O1:12.8|O2:6.0|O1:13.1|O2:1.1|O1:11.5|O2:-0.3|O1:4.2|O2:-2.3|O1:-18.4|O2:-14.0,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Aspartate Transaminase (AST),AST,['Aspartate Transaminase (AST)'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) ,4189605,Aspartate transaminase level,Condition,outcome_113
118,NCT04280705,Change From Baseline in Creatinine,O1:475|O2:482|O1:475|O2:482|O1:418|O2:411|O1:335|O2:309|O1:269|O2:234|O1:249|O2:262|O1:189|O2:229,O1:0.037|O2:0.038|O1:-0.695|O2:0.075|O1:-0.882|O2:0.158|O1:1.173|O2:0.236|O1:-1.239|O2:0.319|O1:-1.863|O2:0.075,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Creatinine,Creatinine,['Creatinine'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",42593557,Urine creatinine increased,Condition,outcome_74
119,NCT04280705,Change From Baseline in Glucose,O1:456|O2:459|O1:456|O2:459|O1:407|O2:395|O1:323|O2:301|O1:260|O2:228|O1:241|O2:250|O1:180|O2:219,O1:-0.2|O2:-3.0|O1:6.3|O2:2.1|O1:2.2|O2:3.2|O1:1.0|O2:-0.1|O1:-2.8|O2:-2.9|O1:-13.5|O2:-11.7,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Glucose,Glucose,['Glucose'],Time Frame: Day 1 through Day 29 ,45770408,Baseline blood glucose concentration,Measurement,outcome_75
120,NCT04280705,Change From Baseline in Hemoglobin,O1:475|O2:475|O1:475|O2:475|O1:420|O2:406|O1:334|O2:310|O1:269|O2:230|O1:253|O2:260|O1:189|O2:227,O1:-0.52|O2:-0.69|O1:-0.83|O2:-0.99|O1:-1.22|O2:-0.49|O1:-1.66|O2:-1.29|O1:-1.51|O2:-1.02|O1:-1.02|O2:-1.21,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Hemoglobin,Hemoglobin,['Hemoglobin'],Time Frame: Day 1 through Day 29 ,4289753,Hemoglobin H,Observation,outcome_76
121,NCT04280705,Change From Baseline in Platelets,O1:471|O2:474|O1:471|O2:474|O1:419|O2:403|O1:332|O2:308|O1:269|O2:229|O1:252|O2:258|O1:189|O2:224,O1:39.3|O2:46.0|O1:76.5|O2:90.1|O1:111.8|O2:130.8|O1:109.3|O2:101.0|O1:96.5|O2:71.1|O1:32.7|O2:39.6,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Platelets,Platelet,"['Platelets', 'Platelet']","Time Frame: From date of randomization until first positive culture or clinical diagnosis of infection if occurs, assessed up to 3 months ",36879118,human platelets,Drug,outcome_114
122,NCT04280705,Change From Baseline in Prothrombin Time (PT),O1:339|O2:352|O1:339|O2:352|O1:296|O2:306|O1:246|O2:234|O1:199|O2:182|O1:176|O2:193|O1:134|O2:163,O1:-0.18|O2:0.44|O1:-0.30|O2:1.15|O1:0.01|O2:1.43|O1:0.86|O2:1.88|O1:0.34|O2:-0.03|O1:-0.28|O2:-0.63,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Prothrombin Time (PT),PT,['Prothrombin Time (PT)'],Time Frame: 24 hours after 2000 U dose intranasal heparin ,3034426,Prothrombin time (PT),Measurement,outcome_115
123,NCT04280705,Change From Baseline in Total Bilirubin,O1:451|O2:456|O1:451|O2:456|O1:394|O2:389|O1:315|O2:288|O1:247|O2:220|O1:237|O2:254|O1:178|O2:216,O1:0.08|O2:-0.04|O1:0.58|O2:-0.03|O1:0.22|O2:0.01|O1:0.23|O2:0.07|O1:0.00|O2:0.09|O1:-0.17|O2:-0.12,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Total Bilirubin,Total Bilirubin,['Total Bilirubin'],Time Frame: Pre-SSI to Immediately Post-SSI; Pre-SSI to 3-month follow-up ,4230543,"Bilirubin, total measurement",Measurement,outcome_79
124,NCT04280705,Change From Baseline in White Blood Cell Count (WBC),O1:474|O2:475|O1:474|O2:475|O1:419|O2:405|O1:333|O2:310|O1:268|O2:230|O1:252|O2:260|O1:189|O2:226,O1:18.691|O2:-18.970|O1:9.886|O2:-28.209|O1:27.223|O2:-45.997|O1:1.967|O2:-34.702|O1:56.311|O2:-70.884|O1:-0.898|O2:0.251,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,White Blood Cell Count (WBC),WBC,['White Blood Cell Count (WBC)'],Time Frame: 0 to 24 hours post-dose ,4298431,White blood cell count,Measurement,outcome_116
125,NCT04280705,Change From Baseline in Neutrophils,O1:463|O2:459|O1:463|O2:459|O1:406|O2:389|O1:317|O2:298|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:9.429|O2:-8.093|O1:4.177|O2:-15.067|O1:17.916|O2:-28.179|O1:3.010|O2:-21.773|O1:36.024|O2:-39.988|O1:-1.269|O2:-0.840,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Neutrophils,Neutrophils,['Neutrophils'],Time Frame: Day 14 ,42596538,Toxic change in neutrophil,Condition,outcome_117
126,NCT04280705,Change From Baseline in Lymphocytes,O1:463|O2:459|O1:463|O2:459|O1:406|O2:389|O1:317|O2:299|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:5.883|O2:-7.847|O1:4.064|O2:-11.723|O1:8.006|O2:-15.455|O1:0.393|O2:-12.016|O1:14.793|O2:-23.836|O1:0.668|O2:0.743,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Lymphocytes,Lymphocytes,['Lymphocytes'],Time Frame: 29 days ,36309122,Lymphocytes,Meas Value,outcome_118
127,NCT04280705,Change From Baseline in Monocytes,O1:463|O2:458|O1:463|O2:458|O1:406|O2:388|O1:316|O2:299|O1:257|O2:220|O1:241|O2:253|O1:177|O2:218,O1:2.448|O2:-2.940|O1:1.498|O2:-2.628|O1:2.324|O2:-3.645|O1:0.383|O2:-2.539|O1:6.475|O2:-8.738|O1:0.125|O2:0.117,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Monocytes,Monocytes,['Monocytes'],Time Frame: 5 days ,36310669,Monocytes,Meas Value,outcome_119
128,NCT04280705,Change From Baseline in Basophils,O1:455|O2:452|O1:455|O2:452|O1:394|O2:380|O1:309|O2:293|O1:253|O2:218|O1:235|O2:248|O1:176|O2:216,O1:0.020|O2:0.005|O1:0.038|O2:0.005|O1:0.196|O2:0.005|O1:0.024|O2:0.028|O1:0.158|O2:-0.058|O1:0.040|O2:0.029,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Basophils,Basophils,['Basophils'],Time Frame: From 6th to the end of 10th day ,4099772,Basophilic degeneration,Observation,outcome_84
129,NCT04280705,Change From Baseline in Eosinophils,O1:456|O2:455|O1:456|O2:455|O1:397|O2:387|O1:311|O2:293|O1:254|O2:218|O1:237|O2:251|O1:176|O2:217,O1:0.634|O2:0.016|O1:0.666|O2:-0.066|O1:0.596|O2:-0.221|O1:0.093|O2:-0.088|O1:1.992|O2:-0.420|O1:0.241|O2:0.211,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Eosinophils,Eosinophils,['Eosinophils'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",45884164,Eosinophils,Meas Value,outcome_85
130,NCT04280705,Change in National Early Warning Score (NEWS) From Baseline,O1:499|O2:502|O1:499|O2:502|O1:447|O2:438|O1:348|O2:321|O1:291|O2:254|O1:290|O2:301|O1:151|O2:120|O1:221|O2:251,O1:0.1|O2:-0.3|O1:0.3|O2:-0.4|O1:-0.3|O2:-0.5|O1:-0.3|O2:-0.5|O1:-1.4|O2:-1.7|O1:-1.4|O2:-1.7|O1:-3.2|O2:-3.3,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,National Early Warning Score (NEWS),NEWS,['National Early Warning Score (NEWS)'],Time Frame: Up to 28 days ,44808684,Royal College of Physicians NEWS (national early warning score),Measurement,outcome_86
131,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1,O1:521|O2:541,O1:0|O2:0|O1:30|O2:24|O1:19|O2:18|O1:39|O2:43|O1:12|O2:14|O1:0|O2:0|O1:0|O2:0|O1:0|O2:0|O1:0|O2:1|O1:0|O2:0|O1:1|O2:1,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Baseline (Day 1), Day 7, Day 14 Day 21 & Day 30 ",4138597,Clinical status,Observation,outcome_120
132,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3,O1:521|O2:541,O1:1|O2:1|O1:36|O2:28|O1:17|O2:16|O1:32|O2:37|O1:12|O2:13|O1:0.4|O2:0.2|O1:0|O2:0|O1:0|O2:0.4|O1:0|O2:0|O1:0.2|O2:2|O1:1|O2:2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 ",4138597,Clinical status,Observation,outcome_121
133,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5,O1:521|O2:541,O1:2|O2:2|O1:37|O2:28|O1:14|O2:12|O1:26|O2:28|O1:11|O2:15|O1:1|O2:1|O1:0|O2:0.2|O1:0.2|O2:0|O1:0|O2:0|O1:7|O2:12|O1:2|O2:3,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 ",4138597,Clinical status,Observation,outcome_121
134,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8,O1:521|O2:541,O1:7|O2:3|O1:33|O2:24|O1:9|O2:9|O1:15|O2:17|O1:10|O2:11|O1:1|O2:1|O1:0|O2:0.2|O1:0.2|O2:0|O1:0|O2:0.4|O1:22|O2:30|O1:2|O2:4,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 & Day30 ",4138597,Clinical status,Observation,outcome_121
135,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11,O1:521|O2:541,O1:8|O2:4|O1:28|O2:22|O1:7|O2:6|O1:13|O2:11|O1:6|O2:7|O1:2|O2:2|O1:0.4|O2:0.4|O1:0.2|O2:0|O1:0|O2:0|O1:33|O2:44|O1:2|O2:4,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day7, Day14, Day21 & Day 30 ",4138597,Clinical status,Observation,outcome_122
136,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15,O1:521|O2:541,O1:11|O2:6|O1:22|O2:15|O1:4|O2:4|O1:11|O2:10|O1:6|O2:7|O1:2|O2:3|O1:17|O2:19|O1:22|O2:29|O1:0|O2:0|O1:2|O2:2|O1:3|O2:5,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day7 ,Day 14 ,Day 21, Day 30 ",4138597,Clinical status,Observation,outcome_123
137,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22,O1:521|O2:541,O1:13|O2:9|O1:14|O2:9|O1:2|O2:2|O1:8|O2:5|O1:5|O2:6|O1:1|O2:1|O1:18|O2:19|O1:32|O2:39|O1:0|O2:0|O1:2|O2:3|O1:4|O2:6|O1:0|O2:0.2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day 14, Day 21 & Day 30 ",4138597,Clinical status,Observation,outcome_98
138,NCT04280705,Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29,O1:521|O2:541,O1:15|O2:11|O1:9|O2:6|O1:2|O2:1|O1:4|O2:4|O1:3|O2:3|O1:1|O2:1|O1:19|O2:20|O1:36|O2:46|O1:0.2|O2:0|O1:3|O2:1|O1:5|O2:7|O1:3|O2:2,Placebo|Remdesivir,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: Day 7, Day14, Day 21 and Day 30. ",4138597,Clinical status,Observation,outcome_124
139,NCT04280705,Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs),O1:516|O2:532,O1:57|O2:51,Placebo|Remdesivir,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. ,45884383,Adverse event,Meas Value,outcome_87
140,NCT04280705,Percentage of Participants Reporting Serious Adverse Events (SAEs),O1:516|O2:532,O1:32|O2:24,Placebo|Remdesivir,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. ,4158959,Serious reportable event,Observation,outcome_88
141,NCT04280705,Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics,O1:521|O2:541,O1:30|O2:41|O1:4|O2:3|O1:2|O2:2|O1:21|O2:16,Placebo|Remdesivir,Discontinued,Discontinued,"['Discontinued or Temporarily Suspended From Investigational Therapeutics', 'Discontinued']",Time Frame: Day 1 through Day 29 ,4133895|36309075,Therapeutic|Discontinue,Observation|Meas Value,outcome_94
142,NCT04280705,Duration of Hospitalization,O1:521|O2:541|O1:521|O2:541|O1:443|O2:480,O1:17|O2:12|O1:14|O2:10,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 8 ,46236995,Hospital stay duration,Observation,outcome_125
143,NCT04280705,Duration of New Non-invasive Ventilation or High Flow Oxygen Use,O1:64|O2:52|O1:64|O2:52|O1:50|O2:43,O1:4|O2:3|O1:3|O2:3,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Non-invasive Ventilation or High Flow Oxygen Use ,Oxygen,"['Oxygen', 'New Non-invasive Ventilation or High Flow Oxygen Use', 'Oxygen Use']",Time Frame: Up to 28 days ,4177224,Noninvasive ventilation,Procedure,outcome_126
144,NCT04280705,Duration of New Oxygen Use,O1:28|O2:27|O1:28|O2:27|O1:25|O2:24,O1:5.5|O2:4|O1:3|O2:3.5,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Oxygen Use ,Oxygen,"['Oxygen', 'New Oxygen Use', 'Oxygen Use']",Time Frame: 30 days after clinic discharge ,40493512,Oxygen saturation below reference range,Condition,outcome_127
145,NCT04280705,Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:82|O2:52|O1:82|O2:52|O1:57|O2:39,O1:23|O2:21.5|O1:16|O2:14,Placebo|Remdesivir|Placebo|Remdesivir|Placebo|Remdesivir,New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use ,ECMO,"['Oxygen', 'ECMO', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: 10 days during inhalation ,4052536,Extracorporeal membrane oxygenation,Procedure,outcome_128
146,NCT04280705,Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use,O1:266|O2:307,O1:24|O2:17,Placebo|Remdesivir,Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use,Oxygen,"['Oxygen', 'Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use', 'Oxygen Use']",Time Frame: 28 days after randomization ,1620907,"Hospitalized - severe disease, non-invasive ventilation or high-flow oxygen",Meas Value,outcome_129
147,NCT04280705,Percentage of Participants Requiring New Oxygen Use,O1:63|O2:75,O1:44|O2:36,Placebo|Remdesivir,Participants Requiring New Oxygen Use,Oxygen,"['Oxygen', 'New Oxygen Use', 'Participants Requiring New Oxygen Use', 'Oxygen Use']",Time Frame: 28 days after randomization ,40482644,Oxygen percentage delivered,Observation,outcome_130
148,NCT04280705,Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,O1:364|O2:402,O1:23|O2:13,Placebo|Remdesivir,Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use,ECMO,"['Oxygen', 'ECMO', 'Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use', 'New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use']",Time Frame: 28 days after randomization ,4052536,Extracorporeal membrane oxygenation,Procedure,outcome_131
149,NCT04280705,Mean Change in the Ordinal Scale,O1:518|O2:533,O1:0.2|O2:0.1|O1:0.1|O2:0.0|O1:0.0|O2:-0.2|O1:-0.1|O2:-0.3|O1:-1.4|O2:-1.9|O1:-1.9|O2:-2.4|O1:-2.3|O2:-2.7,Placebo|Remdesivir,Ordinal Scale ,Ordinal Scale,"['Ordinal Scale', 'Mean Change', 'ordinal scale']",Time Frame: assessed on study day 3 ,4062806,Scale,Device,outcome_132
150,NCT04280705,14-day Participant Mortality,O1:521|O2:541,O1:0.12|O2:0.07,Placebo|Remdesivir,Mortality,Death ,['Mortality'],Time Frame: Day 28 ,4249566,Mortality rate,Observation,outcome_133
151,NCT04280705,29-day Participant Mortality,O1:521|O2:541,O1:0.15|O2:0.11,Placebo|Remdesivir,Mortality,Death ,['Mortality'],Time Frame: 28 days ,4249566,Mortality rate,Observation,outcome_106
152,NCT04280705,Time to an Improvement by at Least One Category Using an Ordinal Scale,O1:521|O2:541,O1:9|O2:7,Placebo|Remdesivir,Improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 15 days ,4062806,Scale,Device,outcome_134
153,NCT04280705,Time to an Improvement of at Least Two Categories Using an Ordinal Scale,O1:521|O2:541,O1:14|O2:11,Placebo|Remdesivir,Improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'ordinal scale']",Time Frame: 6 days and 10 Days ,4062806,Scale,Device,outcome_135
154,NCT04280705,"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First",O1:521|O2:541,O1:12|O2:8,Placebo|Remdesivir,Discharge,Discharge,"['discharge', 'Discharge']",Time Frame: Day 15 ,46235136,Discharge time,Observation,outcome_136
155,NCT04332081,Mortality,O1:20|O2:60,O1:10|O2:22,Hyperbaric Oxygen Therapy (HBOT)|Standard of Care,Mortality,Death ,['Mortality'],NA,4249566,Mortality rate,Observation,outcome_137
156,NCT04332081,Need for Mechanical Ventilation,O1:20|O2:60,O1:2|O2:18,Hyperbaric Oxygen Therapy (HBOT)|Standard of Care,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']",NA,4230167,Artificial respiration,Procedure,outcome_138
157,NCT04329923,Time to Release From Quarantine Time,O1:15|O2:13,O1:8|O2:11,Cohort 1 HCQ|Cohort 1 Placebo,Release,Release,[],NA,4015846,Quarantine,Procedure,outcome_139
158,NCT04329923,Time to Hospital Discharge,O1:4|O2:3,O1:5.5|O2:4,Cohort 2 HCQ High Dose|Cohort 2 HCQ Low Dose,discharge,Discharge,"['discharge', 'Discharge', 'Hospital']",NA,4142018,Discharge to hospital,Observation,outcome_140
159,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,O1:64|O2:61,O1:4|O2:4,Cohort 3 HCQ|Cohort 3 Placebo,Infect,Infect,['Infect'],NA,3663281,Lower respiratory infection caused by SARS-CoV-2,Condition,outcome_141
160,NCT04329923,Rate of Housemate Infection,O1:17|O2:17,O1:2|O2:2,Cohort 1 HCQ|Cohort 1 Placebo,Infect,Infect,['Infect'],NA,45885195,Infection,Meas Value,outcome_142
161,NCT04329923,Rate of Hospitalization,O1:17|O2:17,O1:1|O2:0,Cohort 1 HCQ|Cohort 1 Placebo,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,45884746,Hospitalization,Meas Value,outcome_143
162,NCT04329923,Time to Release From Quarantine Time,NA,NA,NA,Release,Release,[],NA,4015846,Quarantine,Procedure,outcome_139
163,NCT04329923,Time to Hospital Discharge,NA,NA,NA,discharge,Discharge,"['discharge', 'Discharge', 'Hospital']",NA,4142018,Discharge to hospital,Observation,outcome_140
164,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,3663281,Lower respiratory infection caused by SARS-CoV-2,Condition,outcome_141
165,NCT04329923,Rate of Housemate Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,45885195,Infection,Meas Value,outcome_142
166,NCT04329923,Rate of Hospitalization,NA,NA,NA,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,45884746,Hospitalization,Meas Value,outcome_143
167,NCT04329923,Time to Release From Quarantine Time,NA,NA,NA,Release,Release,[],NA,4015846,Quarantine,Procedure,outcome_139
168,NCT04329923,Time to Hospital Discharge,NA,NA,NA,discharge,Discharge,"['discharge', 'Discharge', 'Hospital']",NA,4142018,Discharge to hospital,Observation,outcome_140
169,NCT04329923,Number of Health Care Workers Who Developed SARS-COV-2 Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,3663281,Lower respiratory infection caused by SARS-CoV-2,Condition,outcome_141
170,NCT04329923,Rate of Housemate Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,45885195,Infection,Meas Value,outcome_142
171,NCT04329923,Rate of Hospitalization,NA,NA,NA,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,45884746,Hospitalization,Meas Value,outcome_143
172,NCT04410159,Number of Participants With Early Viral Clearance,O1:5|O2:5|O3:5|O4:5,O1:5|O2:4|O3:1|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Viral Clearance,Viral Clearance,['Viral Clearance'],Time Frame: Pre-SSI ,4124760,Clearance,Observation,outcome_144
173,NCT04410159,Number of Participants With Negative RT-PCR Results,O1:5|O2:5|O3:5|O4:5,O1:5|O2:4|O3:2|O4:1,Povidone-iodine|Essential Oils|Tap Water|Control,RT-PCR,RT-PCR,['RT-PCR'],Time Frame: Baseline to Day 29 ,35939556,"Negative/normal, RT-PCR test",Meas Value,outcome_145
174,NCT04410159,Number of Patients That Progress to More Severe Disease,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,More Severe Disease,More Severe Disease,['More Severe Disease'],Time Frame: Day 14 ,2720509,A patient with severe systemic disease,Observation,outcome_146
175,NCT04410159,Number of Patients With Abnormal Radiological Findings,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Abnormal Radiological,Abnormal Radiological,['Abnormal Radiological'],Time Frame: Treatment period of 7 days ((Day 1 to Day 8) ,36311203,No abnormal findings,Meas Value,outcome_147
176,NCT04410159,Number of Patients With Abnormal Laboratory Findings,O1:5|O2:5|O3:5|O4:5,O1:0|O2:0|O3:0|O4:0,Povidone-iodine|Essential Oils|Tap Water|Control,Abnormal Laboratory Findings,Abnormal Laboratory Findings,['Abnormal Laboratory Findings'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,45882227,Laboratory finding,Meas Value,outcome_148
177,NCT04335136,All Cause-death or Invasive Mechanical Ventilation,O1:88|O2:90,O1:9|O2:12,Group A (Active) APN01|Group B (Placebo Control),Death,Death ,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Death']",NA,44790095,Invasive ventilation,Procedure,outcome_149
178,NCT04335136,Lactate Dehydrogenase (LDH) Level,O1:74|O2:74,O1:5.82|O2:5.80,Group A (Active) APN01|Group B (Placebo Control),LDH,LDH,['LDH'],NA,35918092,Serum Lactate Dehydrogenase (LDH) Lab Value,Measurement,outcome_150
179,NCT04335136,Mortality,O1:88|O2:90,O1:9|O2:7,Group A (Active) APN01|Group B (Placebo Control),Mortality,Death ,['Mortality'],NA,4249566,Mortality rate,Observation,outcome_137
180,NCT04335136,Ventilator-free Days (VFD),O1:88|O2:90|O1:88|O2:90|O1:88|O2:90|O1:80|O2:84|O1:88|O2:90|O1:88|O2:90|O1:79|O2:83,O1:17.2|O2:16.7|O1:17.4|O2:16.7|O1:18.9|O2:17.9|O1:25.7|O2:25.1|O1:26.3|O2:25.6|O1:28.2|O2:26.9,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Ventilator-free,Ventilator-free,['Ventilator-free'],NA,44786857,Days on ventilator,Measurement,outcome_151
181,NCT04335136,Time to Death,O1:88|O2:90,NA|NA,Group A (Active) APN01|Group B (Placebo Control),Death,Death ,['Death'],NA,40758416,Time of death,Observation,outcome_152
182,NCT04335136,"Number of Responders, Defined as ≥2 Improvement in World Health Organization (WHO)'s 11-Point Score System at Days 7, 10, 14 and 28",O1:88|O2:90|O1:88|O2:88|O1:86|O2:85|O1:83|O2:85|O1:79|O2:83,O1:2|O2:0|O1:17|O2:13|O1:38|O2:32|O1:72|O2:74,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Improvement,Improvement,"['improvement', 'Improvement']",NA,4308350|2719865|4077703,Improvement of status|WHO|Score,Observation|Device|Observation,outcome_153
183,NCT04335136,Time to Hospital Discharge,O1:88|O2:90,O1:14|O2:14,Group A (Active) APN01|Group B (Placebo Control),discharge,Discharge,"['discharge', 'Discharge', 'Hospital']",NA,4142018,Discharge to hospital,Observation,outcome_140
184,NCT04335136,Viral Ribonucleic Acid (RNA).,O1:88|O2:90|O1:59|O2:49|O1:47|O2:58|O1:56|O2:64|O1:65|O2:61|O1:73|O2:73|O1:37|O2:0,O1:27996|O2:3900|O1:20931|O2:13681|O1:9825|O2:11912|O1:5229|O2:2094|O1:9274|O2:53|O1:36,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Viral Ribonucleic Acid (RNA),RNA,[],NA,4101264,Ribonucleic acid,Observation,outcome_154
185,NCT04335136,Time to a 2-point Decrease in WHO's 11-Point Score System,O1:88|O2:90,O1:27|O2:27,Group A (Active) APN01|Group B (Placebo Control),WHO's 11-Point Score,WHO's 11-Point Score,[],NA,4077703,Score,Observation,outcome_155
186,NCT04335136,Number of Patients With Any Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge,O1:88|O2:90,O1:7|O2:7|O1:86|O2:88,Group A (Active) APN01|Group B (Placebo Control),Invasive Mechanical Ventilation/ Hospital Discharge,Mechanical Ventilation,"['discharge', 'Discharge', 'mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Hospital']",NA,44790095,Invasive ventilation,Procedure,outcome_156
187,NCT04335136,Time to First Use of Invasive Mechanical Ventilation up to 28 Days or Hospital Discharge,O1:88|O2:90,NA|NA,Group A (Active) APN01|Group B (Placebo Control),Invasive Mechanical Ventilation/ Hospital Discharge,Mechanical Ventilation,"['discharge', 'Discharge', 'mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Hospital']",NA,4230167,Artificial respiration,Procedure,outcome_138
188,NCT04335136,PaO2/FiO2 Value,O1:88|O2:90|O1:30|O2:28|O1:19|O2:24|O1:14|O2:13|O1:9|O2:11|O1:1|O2:3,O1:223.07|O2:185.14|O1:218.74|O2:192.21|O1:290.00|O2:186.62|O1:197.00|O2:185.00|O1:261.00|O2:185.00,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),PaO2/FiO2,P/F Ratio,['PaO2/FiO2'],NA,42869590,Oxygen/Gas total [Pure volume fraction] Inhaled gas,Measurement,outcome_157
189,NCT04335136,"Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)",O1:88|O2:90|O1:80|O2:80|O1:83|O2:77|O1:80|O2:77|O1:79|O2:75|O1:39|O2:38,O1:2.6|O2:2.2|O1:1.8|O2:1.6|O1:1.0|O2:1.0|O1:1.0|O2:0.9|O1:0.2|O2:0.8,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),"Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)","Modified Sequential Organ Failure Assessment Score (mSOFA Score, Total Score)",[],NA,36684937,Sequential organ failure assessment score,Measurement,outcome_158
190,NCT04335136,Lymphocyte Count,O1:88|O2:90|O1:82|O2:82|O1:85|O2:83|O1:82|O2:80|O1:81|O2:75|O1:77|O2:73|O1:37|O2:37,O1:1.13|O2:1.06|O1:1.25|O2:1.16|O1:1.45|O2:1.62|O1:1.74|O2:1.79|O1:1.70|O2:1.71|O1:2.28|O2:1.72,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),Lymphocyte Count,Lymphocyte Count,['Lymphocyte Count'],NA,37393858,Lymphocyte count,Measurement,outcome_159
191,NCT04335136,C-reactive Protein Levels,O1:88|O2:90|O1:77|O2:79|O1:80|O2:74|O1:78|O2:76|O1:74|O2:71|O1:69|O2:73|O1:36|O2:37,O1:56.0|O2:62.8|O1:36.1|O2:43.7|O1:21.7|O2:26.1|O1:13.9|O2:26.3|O1:15.8|O2:38.3|O1:4.9|O2:8.5,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),C-reactive Protein,CRP,['C-reactive Protein'],NA,4208414,C-reactive protein measurement,Measurement,outcome_160
192,NCT04335136,D-Dimer,O1:88|O2:90|O1:71|O2:73|O1:69|O2:74|O1:73|O2:68|O1:70|O2:66|O1:70|O2:66|O1:32|O2:31,O1:1341|O2:1187|O1:1109|O2:881|O1:1208|O2:1139|O1:988|O2:1219|O1:1015|O2:1013|O1:573|O2:685,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),D-dimer,D-dimer,['D-dimer'],NA,37393605,D-dimer level,Measurement,outcome_161
193,NCT04335136,Log-transformed Levels of LDH,O1:88|O2:90|O1:78|O2:77|O1:76|O2:76|O1:78|O2:74|O1:72|O2:74|O1:69|O2:71|O1:38|O2:38,O1:5.91|O2:5.87|O1:5.86|O2:5.88|O1:5.77|O2:5.75|O1:5.66|O2:5.67|O1:5.55|O2:5.52|O1:5.43|O2:5.50,Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control)|Group A (Active) APN01|Group B (Placebo Control),LDH,LDH,['LDH'],NA,4210717,Serum lactate dehydrogenase measurement,Measurement,outcome_162
194,NCT04331366,Oxygen Saturation by Pulse Oximetry,O1:2,O1:92|O1:93.5|O1:94|O1:94|O1:92.5,GO2 PEEP MOUTHPIECE,Oxygen Saturation,SpO2,"['Oxygen', 'Oxygen Saturation']",Time Frame: 28 days after randomization ,40762498,Oxygen saturation in Blood Preductal by Pulse oximetry,Measurement,outcome_163
195,NCT04331366,Respiratory Rate,O1:2,O1:23.5|O1:20|O1:18|O1:17|O1:18.5,GO2 PEEP MOUTHPIECE,Respiratory Rate,Respiratory Rate,['Respiratory Rate'],Time Frame: Baseline to Day 29 ,4313591,Respiratory rate,Measurement,outcome_164
196,NCT04331366,Heart Rate,O1:2,O1:84.5|O1:87.5|O1:90.5|O1:86.5|O1:86.5,GO2 PEEP MOUTHPIECE,Heart Rate,Heart Rate,['Heart Rate'],Time Frame: Day 1 through Day 29 ,4239408,Heart rate,Measurement,outcome_165
197,NCT04331366,Blood Pressure,O1:2,O1:152.5|O1:65|O1:155|O1:72.5|O1:150|O1:70|O1:145|O1:67.5|O1:152.5|O1:65,GO2 PEEP MOUTHPIECE,Blood Pressure,Blood Pressure,['Blood Pressure'],Time Frame: Baseline ,4326744,Blood pressure,Measurement,outcome_166
198,NCT04331366,Count of Participants With Subjective Work of Breathing,O1:2|O1:0|O1:2|O1:2|O1:2|O1:0,O1:1|O1:0|O1:0,GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE|GO2 PEEP MOUTHPIECE,Subjective Work of Breathing,Breathing,['Subjective Work of Breathing'],Time Frame: Days 1 - 17. ,21499243,Breathing,Meas Value,outcome_167
199,NCT04331899,Duration Until Viral Shedding Cessation,O1:60|O2:60,O1:7|O2:7,Lambda|Placebo,Viral Shedding,Viral Clearance,['Viral Shedding'],Time Frame: 0 to 24 hours post-dose ,4201079,Patient shedding virus,Condition,outcome_168
200,NCT04331899,Change in Sars-CoV-2 Viral Load,O1:60|O2:60,O1:-4.3|O2:-4.9,Lambda|Placebo,Viral Load,Viral Load,['Viral Load'],Time Frame: Pre-SSI to 3-month follow-up ,37393279,Viral load,Measurement,outcome_169
201,NCT04331899,Area Under the Curve of SARS-COV-2 Viral Load,O1:60|O2:60,O1:28.5|O2:29.6,Lambda|Placebo,Viral Load,Viral Load,['Viral Load'],Time Frame: Pre-SSI to 3-month follow-up ,37311062,Antigen of SARS-CoV-2,Observation,outcome_170
202,NCT04331899,Duration Until Resolution of Symptoms,O1:60|O2:60,O1:8|O2:9,Lambda|Placebo,Resolution of Symptoms,Resolution of Symptoms,"['Symptom', 'Resolution of Symptoms']","Time Frame: Baseline, Days 4, 7, 15, 21, and 29 ",4037328,Time symptom lasts,Observation,outcome_171
203,NCT04331899,Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment,O1:60|O2:60,O1:2|O2:2|O1:5|O2:3,Lambda|Placebo,hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 22 ,45883971,Hospital emergency department,Meas Value,outcome_172
204,NCT04292899,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14,O1:200|O2:197,O1:8.0|O2:10.7|O1:8.5|O2:16.8|O1:4.0|O2:5.1|O1:9.5|O2:7.6|O1:6.0|O2:6.1|O1:4.0|O2:1.5|O1:60.0|O2:52.3,Part A: Remdesivir (RDV) for 5 Days|Part A: Remdesivir for 10 Days,ordinal scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']","Time Frame: days 1, 5 and 14 ",4138597,Clinical status,Observation,outcome_173
205,NCT04292899,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),O1:200|O2:197,O1:71.5|O2:75.1,Part A: Remdesivir (RDV) for 5 Days|Part A: Remdesivir for 10 Days,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. ,45884383,Adverse event,Meas Value,outcome_174
206,NCT04292730,Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11,O1:191|O2:193|O3:200,O1:0.0|O2:1.0|O3:2.0|O1:0.0|O2:0.5|O3:2.0|O1:2.6|O2:0.0|O3:3.5|O1:3.7|O2:6.2|O3:5.5|O1:19.9|O2:22.8|O3:23.0|O1:3.7|O2:4.7|O3:4.0|O1:70.2|O2:64.8|O3:60.0,Part A: Remdesivir for 5 Days|Part A: Remdesivir for 10 Days|Part A: SOC Therapy,ordinal scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: 14 days ,4138597,Clinical status,Observation,outcome_105
207,NCT04292730,Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs),O1:191|O2:193|O3:200,O1:51.3|O2:58.5|O3:46.5,Part A: Remdesivir for 5 Days|Part A: Remdesivir for 10 Days|Part A: SOC Therapy,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']","Time Frame: The duration of hospitalization for the patients (admission to discharge dates, approximately 4-14 days after admission). The patients who died were excluded. ",45884383,Adverse event,Meas Value,outcome_175
208,NCT04320615,Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4),O1:294|O2:144,Tocilizumab (TCZ) mITT Arm|Placebo Modified Intent-to-Treat (mITT) Arm,NA,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA,4138597,Clinical status,Observation,outcome_176
209,NCT04320615,"Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours",O1:294|O2:144,NA,NA,Improvement,Improvement,"['improvement', 'Improvement', 'National Early Warning Score 2']",NA,37208353,Royal College of Physicians NEWS2 (National Early Warning Score 2) total score,Measurement,outcome_177
210,NCT04320615,Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status,O1:294|O2:144,NA,NA,Improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'ordinal scale']",NA,4138597,Clinical status,Observation,outcome_178
211,NCT04320615,"Time to Hospital Discharge or ""Ready for Discharge""",O1:294|O2:144,NA,NA,discharge,Discharge,"['discharge', 'Discharge', 'Hospital']",NA,4325701,Ready for discharge,Observation,outcome_179
212,NCT04320615,Incidence of Mechanical Ventilation by Day 28,O1:294|O2:144|O3:183|O4:90,NA,NA,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']",NA,4230167,Artificial respiration,Procedure,outcome_138
213,NCT04320615,Ventilator-Free Days to Day 28,O1:294|O2:144,NA,NA,Ventilator-free,Ventilator-free,['Ventilator-free'],NA,44786857,Days on ventilator,Measurement,outcome_151
214,NCT04320615,Incidence of Intensive Care Unit (ICU) Stay by Day 28 (Week 4),O1:294|O2:144|O3:127|O4:64,NA,NA,ICU,ICU,"['Intensive Care', 'ICU']",NA,36311219,Intensive care unit (ICU),Meas Value,outcome_180
215,NCT04320615,Duration of ICU Stay to Day 28 (Week 4),O1:294|O2:144,NA,NA,ICU,ICU,['ICU'],NA,44786856,Days in intensive care unit,Observation,outcome_181
216,NCT04320615,Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 14,O1:294|O2:144,NA,NA,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA,4138597,Clinical status,Observation,outcome_176
217,NCT04320615,Time to Clinical Failure to Day 28 (Week 4),O1:294|O2:144,NA,NA,Time,Time,[],NA,45881190,Failure,Meas Value,outcome_182
218,NCT04320615,Mortality Rate at Day 28 (Week 4),O1:294|O2:144,NA,NA,Mortality,Death ,"['Mortality Rate', 'Mortality']",NA,4249566,Mortality rate,Observation,outcome_137
219,NCT04320615,Time to Recovery to Day 28 (Week 4),O1:294|O2:144,NA,NA,Recovery,Recovery,"['Recovery', 'Time to Recovery']",NA,31999,Recovered,Cost,outcome_183
220,NCT04320615,Duration of Supplemental Oxygen to Day 28 (Week 4),O1:294|O2:144,NA,NA,Oxygen,Oxygen,['Oxygen'],NA,36308581,Supplemental oxygen,Meas Value,outcome_13
221,NCT04401202,Percentage of Participants With Clinical Recovery Within 14 Days After Randomization,O1:87|O2:86,O1:54|O2:31,Nigella Sativa Oil|Control,Recovery,Recovery,['Recovery'],"Time Frame: Day 0 through Day 2, acute phase ",31999,Recovered,Cost,outcome_184
222,NCT04401202,The Number of Days to Recovery,O1:87|O2:86,O1:11|O2:14,Nigella Sativa Oil|Control,Recovery,Recovery,['Recovery'],"Time Frame: Day 1 through Day 15, chronic phase ",31999,Recovered,Cost,outcome_185
223,NCT04401202,Duration of Each Symptom,O1:87|O2:86,O1:8.5|O2:10.4|O1:2.5|O2:3.7|O1:3.5|O2:5.5|O1:2.1|O2:4.9,Nigella Sativa Oil|Control,Symptom,Symptom,['Symptom'],Time Frame: 14 days ,4037328,Time symptom lasts,Observation,outcome_186
224,NCT04401202,Side Effects,O1:87|O2:86,O1:3|O2:0,Nigella Sativa Oil|Control,Effect,Effect,['Effect'],Time Frame: Day 1 through Day 29 ,36308802,Side effects,Meas Value,outcome_187
225,NCT04401202,Hospital Admission Due to Disease Complications,O1:87|O2:86,O1:0|O2:4,Nigella Sativa Oil|Control,Complication,Complication,"['Complication', 'Hospital']",Time Frame: 7 days ,8715,Hospital admission,Observation,outcome_188
226,NCT04435808,SARS-CoV-2 Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,37311065,SARS-CoV-2,Observation,outcome_189
227,NCT04435808,Symptomatic vs. Asymptomatic Infection With SARS-CoV-2,NA,NA,NA,Symptom,Symptom,"['Symptom', 'Infect']",NA,3662381,Asymptomatic SARS-CoV-2,Condition,outcome_190
228,NCT04435808,Occupational Health Exposure,NA,NA,NA,Health Exposure,Health Exposure,[],NA,46238109,Occupational Health,Meas Value,outcome_191
229,NCT04435808,Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection,NA,NA,NA,Hospitalization,Hospitalization,"['Hospitalization', 'Infect', 'hospitalization', 'Hospital']",NA,1777087,hydroxychloroquine,Drug,outcome_192
230,NCT04435808,Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection,NA,NA,NA,ICU,ICU,"['Infect', 'ICU']",NA,1777087,hydroxychloroquine,Drug,outcome_193
231,NCT04435808,Adverse Effect Profile of Hydroxychloroquine,NA,NA,NA,Adverse,Adverse,"['Effect', 'Adverse']",NA,4098402,Hydroxychloroquine adverse reaction,Observation,outcome_194
232,NCT04435808,Seroconversion Following SARS-CoV-2 Infection,NA,NA,NA,Infect,Infect,['Infect'],NA,704991,Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Blood,Measurement,outcome_195
233,NCT04435808,Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates,NA,NA,NA,Sequencing,Sequencing,[],NA,704993,Measurement of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using Sequencing,Measurement,outcome_196
234,NCT04338074,Hospitalization,O1:3|O2:2,O1:0|O2:0,Tranexamic Acid Treatment|Placebo Treatment,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,45884746,Hospitalization,Meas Value,outcome_143
235,NCT04338074,NA,NA,NA,NA,nan,nan,['nan'],NA,NA,NA,NA,outcome_197
236,NCT04358068,Number of Participants Who Died From Any Cause or Were Hospitalized,O1:7|O2:9,O1:0|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,['Hospital'],NA,4249566,Mortality rate,Observation,outcome_137
237,NCT04358068,Number of Participants Who Died From Any Cause,O1:7|O2:9,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,[],NA,4249566,Mortality rate,Observation,outcome_137
238,NCT04358068,"Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic",O1:7|O2:9,O1:1|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,['Hospital'],NA,4249566,Mortality rate,Observation,outcome_137
239,NCT04358068,Number of Participants Who Died From Any Cause or Were Hospitalized Through the End of Follow-up,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Died,Death ,['Hospital'],NA,1147312,death,Metadata,outcome_198
240,NCT04358068,Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event,O1:7|O2:9,O1:0|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Adverse,Adverse,"['Adverse', 'Adverse Event']",NA,45884383,Adverse event,Meas Value,outcome_199
241,NCT04358068,Number of Participants Who Had Any Cardiac Adverse Events,O1:7|O2:9,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,45884383,Adverse event,Meas Value,outcome_199
242,NCT04358068,Duration of Fever,O1:7|O2:8,O1:0|O2:0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Fever ,Fever ,['Fever'],NA,21495022,Fever duration,Observation,outcome_200
243,NCT04358068,Duration of Symptoms Associated With COVID-19 Disease,O1:7|O2:9,O1:11.0|O2:10.0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Symptom,Symptom,['Symptom'],NA,1333343,COVID-19 Related Symptoms,Observation,outcome_201
244,NCT04358068,Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time,O1:7|O2:9,O1:4.0|O2:2.8,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Symptom,Symptom,['Symptom'],NA,21494066,Symptom score [AUASI],Observation,outcome_202
245,NCT04358068,Time to Self-reported Return to Usual (Pre-COVID) Health.,O1:7|O2:9,O1:17.0|O2:10.0,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Time,Time,[],NA,764573,Self-reported,Observation,outcome_203
246,NCT04358068,SARS-CoV-2 RNA Detection Status From Self-collected Nasal and Site-collected NP Swabs Among Subset,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Detection,Detection ,['Detection'],NA,715261,SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing,Measurement,outcome_204
247,NCT04358068,SARS-CoV-2 RNA Level (Continuous) From Self-collected Nasal and Site-collected NP Swabs Among Subset,O1:0|O2:0,NA,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,RNA,RNA,[],NA,715261,SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing,Measurement,outcome_205
248,NCT04358068,Number of Participants With an Occurrence of Fainting,O1:7|O2:9,O1:1|O2:1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|Arm B: Placebo for Hydroxychloroquine and Azithromycin,Fainting,Fainting,[],NA,4323504,Clinical trial participant,Observation,outcome_206
249,NCT04358081,Number of Participants Who Achieved Clinical Response by Day 15,O1:7|O2:7|O3:5,O1:7|O2:7|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Clinical Response,Clinical Response,['Clinical Response'],Time Frame: Baseline ,4138597,Clinical status,Observation,outcome_207
250,NCT04358081,Number of Participants Who Achieved Viral Clearance,O1:7|O2:7|O3:5,O1:2|O2:3|O3:3|O1:2|O2:3|O3:3,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Viral Clearance,Viral Clearance,['Viral Clearance'],Time Frame: Pre-SSI ,4124760,Clearance,Observation,outcome_144
251,NCT04358081,Number of Participants Discharged or Ready for Discharge,O1:7|O2:7|O3:5,O1:7|O2:7|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Discharge ,Discharge,"['discharge', 'Discharge']",Time Frame: Day 1 through Day 29 ,4325701,Ready for discharge,Observation,outcome_208
252,NCT04358081,Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo,O1:7|O2:7|O3:5,O1:7|O2:6|O3:4,Arm 1: Hydroxychloroquine + Aithromycin Placebo|Arm 2: Hydroxychloroquine + Azithromycin|Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,Oxygen,Oxygen,['Oxygen'],Time Frame: Enrollment to Day 28 ,45884194,Receiving supplemental oxygen,Meas Value,outcome_209
253,NCT04523831,Number of Patients With Early Clinical Improvement,O1:183|O2:180,O1:111|O2:80,Ivermectin Plus Doxycycline|Placebo,Improvement ,Improvement,"['improvement', 'Improvement']",Time Frame: Day 6 ,35621943,Patient Global Impression of Improvement,Measurement,outcome_210
254,NCT04523831,Number of Participants With Late Clinical Recovery,O1:183|O2:180,O1:42|O2:67,Ivermectin Plus Doxycycline|Placebo,Recovery,Recovery,['Recovery'],"Time Frame: Day 0 through Day 2, acute phasNumber of Incidents of Epistaxis, Chronic Phase|Time Frame: Day 1 through Day 15, chronic phase ",31999,Recovered,Cost,outcome_211
255,NCT04523831,Number of Patients Having Clinical Deterioration.,O1:183|O2:180,O1:16|O2:32,Ivermectin Plus Doxycycline|Placebo,Deterioration,Deterioration,['Deterioration'],Time Frame: Day 1 ,4111347,General health deterioration,Condition,outcome_212
256,NCT04523831,Number of Patients Remain Persistently Positive for RT-PCR of Covid-19,O1:183|O2:180,O1:14|O2:36,Ivermectin Plus Doxycycline|Placebo,RT-PCR,RT-PCR,"['Positive', 'RT-PCR']",Time Frame: Baseline to Day 29 ,35936593,Positive on RT-PCR and IHC,Meas Value,outcome_213
257,NCT04599959,Number of Participants Testing Positive or Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Mexico,O1:151|O2:103,O1:85|O2:13|O1:66|O2:89|O1:0|O2:1,Swab - Processed in Mexico|Saliva - Processed in Mexico,Positive,Positive,['Positive'],NA,703439,Taking of swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),Procedure,outcome_214
258,NCT04599959,Percentage of Participants Testing True Positive or True Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Germany,O1:141|O1:69|O1:72,O1:52.2|O1:100.0,Swab+Saliva - Processed in Germany|Swab+Saliva - Processed in Germany|Swab+Saliva - Processed in Germany,Positive,Positive,['Positive'],NA,703439,Taking of swab for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),Procedure,outcome_214
259,NCT04343092,Number of Cured Patients,O1:16,O1:16,IVM+HCQ+AZT Group,cure,cure,['cure'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4159637,Patient cured,Condition,outcome_215
260,NCT04343092,Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group,O1:16,O1:7.62,IVM+HCQ+AZT Group,cure,cure,['cure'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",31999,Recovered,Cost,outcome_216
261,NCT04362137,"Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care",O1:284|O2:144,O1:34|O2:17,Ruxolitinib 5 mg|Placebo,ICU,ICU,"['mechanical Ventilation', 'Mechanical Ventilation', 'Intensive Care', 'ICU']",NA,36311219,Intensive care unit (ICU),Meas Value,outcome_180
262,NCT04362137,Clinical Status,O1:287|O2:145|O1:286|O2:145|O1:280|O2:142|O1:278|O2:142,O1:3.7|O2:3.7|O1:1.8|O2:1.8|O1:1.1|O2:1.0,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Clinical Status ,Clinical Status ,['Clinical Status'],Time Frame: Baseline ,4138597,Clinical status,Observation,outcome_217
263,NCT04362137,Percentage of Patients With at Least Two-point Improvement From Baseline in Clinical Status,O1:286|O2:145,O1:206|O2:108|O1:252|O2:129,Ruxolitinib 5 mg|Placebo,improvement,Improvement,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 ,4138597,Clinical status,Observation,outcome_218
264,NCT04362137,Percentage of Patients With at Least One-point Improvement From Baseline in Clinical Status,O1:286|O2:145,O1:250|O2:128|O1:261|O2:136,Ruxolitinib 5 mg|Placebo,improvement,Improvement,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 ,4308350,Improvement of status,Observation,outcome_219
265,NCT04362137,Percentage of Patients With at Least One-point Deterioration From Baseline in Clinical Status,O1:286|O2:145,O1:16|O2:9|O1:14|O2:5,Ruxolitinib 5 mg|Placebo,Deterioration,Deterioration,"['Deterioration', 'Clinical Status']",Time Frame: Day 3 ,4138597,Clinical status,Observation,outcome_220
266,NCT04362137,Time to Improvement in Clinical Status,O1:286|O2:145,O1:9.0|O2:9.0,Ruxolitinib 5 mg|Placebo,improvement,Improvement,"['improvement', 'Improvement', 'Clinical Status']",Time Frame: Day 14 ,4138597,Clinical status,Observation,outcome_218
267,NCT04362137,Mean Change From Baseline in the Clinical Status,O1:287|O2:145|O1:280|O2:142|O1:278|O2:142,O1:-1.96|O2:-1.93|O1:-2.61|O2:-2.69,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Mean Change,Mean Change,"['Clinical Status', 'Mean Change']",Time Frame: Day 1 - Day 29 ,4138597,Clinical status,Observation,outcome_221
268,NCT04362137,Mortality Rate,O1:287|O2:145|O1:286|O2:145|O1:286|O2:145,O1:6|O2:2|O1:9|O2:3,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Mortality,Death ,"['Mortality Rate', 'Mortality']",Time Frame: during the survey administration ,4249566,Mortality rate,Observation,outcome_222
269,NCT04362137,Proportion of Patients Requiring Mechanical Ventilation,O1:286|O2:145,O1:22|O2:10,Ruxolitinib 5 mg|Placebo,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']",Time Frame: 29 days ,3190682,Requires mechanical ventilatory assistance,Condition,outcome_223
270,NCT04362137,Duration of Hospitalization,O1:286|O2:145,O1:9.0|O2:9.0,Ruxolitinib 5 mg|Placebo,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 29 ,46236995,Hospital stay duration,Observation,outcome_224
271,NCT04362137,Time to Hospital Discharge or to a NEWS2 Score of ≤2,O1:286|O2:145,O1:4.0|O2:4.0,Ruxolitinib 5 mg|Placebo,discharge,Discharge,"['NEWS2 Score', 'discharge', 'Discharge', 'Hospital']",Time Frame: Day 29 ,4142018,Discharge to hospital,Observation,outcome_225
272,NCT04362137,Change From Baseline in NEWS2 Score,O1:287|O2:145|O1:264|O2:135|O1:230|O2:120|O1:175|O2:91|O1:113|O2:66|O1:257|O2:132|O1:234|O2:122,O1:-0.7|O2:-0.6|O1:-1.0|O2:-0.8|O1:-1.3|O2:-1.3|O1:-1.1|O2:-1.3|O1:-1.9|O2:-2.2|O1:-2.3|O2:-2.5,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,NEWS2 Score,NEWS2 Score,['NEWS2 Score'],Time Frame: At the begining of inhalation (day 1) and on next day of last inhalation (day 11) ,37208354,Royal College of Physicians NEWS2 (National Early Warning Score 2),Measurement,outcome_226
273,NCT04362137,Change From Baseline in SpO2/FiO2 Ratio,O1:287|O2:145|O1:260|O2:132|O1:232|O2:124,O1:90.110|O2:106.766|O1:105.553|O2:109.710,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,SpO2/FiO2 Ratio ,SpO2/FiO2 Ratio ,"['SpO2', 'SpO2/FiO2 Ratio']",Time Frame: Days 1 - 29. ,4353936|45770406,Inspired oxygen concentration|Baseline SpO2 (oxygen saturation at periphery),Measurement|Measurement,outcome_227
274,NCT04362137,Proportion of Patients With no Oxygen Therapy,O1:287|O2:145|O1:274|O2:140|O1:269|O2:139,O1:255|O2:133|O1:262|O2:136,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,no Oxygen Therapy ,Oxygen,"['Oxygen', 'Oxygen Therapy', 'no Oxygen Therapy']",Time Frame: At the beginning of inhalation (day 1) and on next day of last inhalation (day 11) ,36311244,Oxygen therapy,Meas Value,outcome_228
275,NCT04362137,All Collected Deaths,O1:287|O2:145|O1:281|O2:143|O1:287|O2:145,O1:9|O2:3|O1:9|O2:3,Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo|Ruxolitinib 5 mg|Placebo,Death,Death ,['Death'],NA,1147312,death,Metadata,outcome_198
276,NCT04724538,Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:11.2|O2:9.8|O1:9.7|O2:8.7|O1:8.8|O2:9.3,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,4016934,"WBC differential count, peripheral blood buffy coat smear",Measurement,outcome_229
277,NCT04724538,Count of Red Blood Cells (RBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:4.5|O2:4.5|O1:4.3|O2:4.4|O1:4.2|O2:4.4,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,4030871,Red blood cell count,Measurement,outcome_230
278,NCT04724538,Hemoglobin Count (Hb) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:140.5|O2:132|O1:137.5|O2:130.6|O1:135.3|O2:131,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event', 'Hemoglobin']",NA,2615333|4244232,"Technetium tc-99m pertechnetate, diagnostic, per millicurie|Hemoglobin",Device|Observation,outcome_231
279,NCT04724538,Percentage of Neutrophils (N) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:76.3|O2:72.2|O1:68.8|O2:72.2|O1:68.4|O2:71.5,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Neutrophils,Neutrophils,"['Adverse Events', 'Adverse', 'Neutrophils', 'Adverse Event']",NA,36308680|2615333,"Neutrophils|Technetium tc-99m pertechnetate, diagnostic, per millicurie",Meas Value|Device,outcome_232
280,NCT04724538,Absolute Neutrophil Count (ANC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:8.8|O2:7.4|O1:6.8|O2:6.6|O1:6.2|O2:6.9,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,2615333|37393856,"Technetium tc-99m pertechnetate, diagnostic, per millicurie|Neutrophil count",Device|Measurement,outcome_233
281,NCT04724538,Absolute Lymphocyte Count (ALC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:1.6|O2:1.6|O1:2.1|O2:1.4|O1:1.64|O2:1.73,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event', 'Lymphocyte Count']",NA,2615333|37393858,"Technetium tc-99m pertechnetate, diagnostic, per millicurie|Lymphocyte count",Device|Measurement,outcome_234
282,NCT04724538,Level of Lactate in the Blood After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:5|O2:4.11|O1:4.4|O2:4.6|O1:4.28|O2:4.81,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,2615333,"Technetium tc-99m pertechnetate, diagnostic, per millicurie",Device,outcome_235
283,NCT04724538,Level of D-dimer in Blood After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With COVID-19 Viral Pneumonia.,O1:11|O2:14,O1:1737|O2:1284|O1:843|O2:685|O1:383|O2:859,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,D-dimer,D-dimer,"['Adverse Events', 'D-dimer', 'Adverse', 'Adverse Event']",NA,2615333|37393605,"Technetium tc-99m pertechnetate, diagnostic, per millicurie|D-dimer level",Device|Measurement,outcome_236
284,NCT04724538,Level of CD4+ T-cells in Blood After 99mTc-pertechnetate Aerosol Inhalation for Evaluation of Cellular Immune Response After This Procedure in Patients With COVID-19 Viral Pneumonia,O1:11|O2:14,O1:761|O2:614|O1:1100|O2:832|O1:845|O2:718,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,CD4+,CD4+,['CD4+'],NA,4017426,T lymphocyte positive for CD4 antigen,Spec Anatomic Site,outcome_237
285,NCT04724538,Level of NK-cells in Blood After 99mTc-pertechnetate Aerosol Inhalation for Evaluation of Cellular Immune Response After This Procedure in Patients With COVID-19 Viral Pneumonia,O1:11|O2:14,O1:153|O2:164|O1:188|O2:149|O1:219|O2:181,Patient With COVID-19 Pneumonia|Patient With COVID-19 Pneumonia Without Intervention,NK-cells,NK-cells,[],NA,4125090|2615333,"NK-cell|Technetium tc-99m pertechnetate, diagnostic, per millicurie",Spec Anatomic Site|Device,outcome_238
286,NCT04674644,The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale,O1:813,O1:18.48,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,Fear,Fear,"['Fear', 'Effect', 'Psychosocial']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4338514,Psychosocial status,Observation,outcome_239
287,NCT04674644,The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale,O1:813,O1:2.17,The Psychosocial Effects of COVID-19 Using the Turkish Version of the Coronavirus Anxiety Scale,Psychosocial ,Psychosocial ,"['Effect', 'Psychosocial']","Time Frame: Day 14, chronic phase ",1616551,Coronavirus anxiety scale,Observation,outcome_240
288,NCT04345653,Recruitment Feasibility,O1:46,O1:46,Study Arm,Recruitment Feasibility ,Recruitment Feasibility ,['Recruitment Feasibility'],Time Frame: Baseline to Day 29 ,139830,Recruitment,Condition,outcome_241
289,NCT04345653,Resource Utilization,O1:46,O1:46,Study Arm - Hydroxychloroquine Sulfate (HCQ),Resource Utilization ,Resource Utilization ,['Resource Utilization'],Time Frame: Baseline to Day 29 ,44810591,Johns Hopkins Adjusted Clinical Groups - Resource Utilization Band category,Measurement,outcome_242
290,NCT04345653,Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events,O1:46,O1:0|O1:24,Study Arm - Hydroxychloroquine Sulfate (HCQ),Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: 22 days after randomization. ,45884383,Adverse event,Meas Value,outcome_87
291,NCT04345653,Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC.,O1:46,O1:0,Study Arm - Hydroxychloroquine Sulfate (HCQ),Early Feasibility,Early Feasibility,['Early Feasibility'],"Time Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29 ",37311061,COVID-19,Condition,outcome_243
292,NCT04338009,Hierarchical Composite Endpoint,O1:77|O2:75,O1:81|O2:73,Discontinuation Arm|Continuation Arm,Hierarchical Composite,Hierarchical Composite,['Hierarchical Composite'],Time Frame: Day 1 through Day 29 ,4034846,Composite,Observation,outcome_244
293,NCT04338009,All-Cause Death,O1:77|O2:75,O1:10|O2:11,Discontinuation Arm|Continuation Arm,Death ,Death ,['Death'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",36031791,All-cause deaths since start of event,Measurement,outcome_245
294,NCT04338009,Length of Hospital Stay,O1:77|O2:75,O1:5|O2:6,Discontinuation Arm|Continuation Arm,Hospital ,Hospitalization,['Hospital'],Time Frame: Day 3 ,46236995,Hospital stay duration,Observation,outcome_246
295,NCT04338009,"Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation",O1:77|O2:75,O1:15|O2:13,Discontinuation Arm|Continuation Arm,"ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation ",ICU,"['Oxygen', 'mechanical Ventilation', 'Mechanical Ventilation', 'ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation', 'Invasive Mechanical Ventilation', 'ICU']","Time Frame: Days 15, 21, 28 ",4052536,Extracorporeal membrane oxygenation,Procedure,outcome_247
296,NCT04338009,AUC SOFA,O1:77|O2:75,O1:7|O2:12,Discontinuation Arm|Continuation Arm,AUC SOFA ,AUC SOFA ,['AUC SOFA'],"Time Frame: Through study completion, an average of 3 months ",4086150|4323504|4086150,Parameter|Clinical trial participant|Parameter,Observation|Observation|Observation,outcome_248
297,NCT04342663,Number of Participants Who Met Clinical Worsening,O1:80|O2:72,O1:0|O2:6,Fluvoxamine|Placebo,Clinical Worsening,Clinical Worsening,[],NA,4323504,Clinical trial participant,Observation,outcome_249
298,NCT04342663,Clinical Deterioration on a Likert-type Scale (0-6),O1:80|O2:72,O1:80|O2:66|O1:0|O2:2|O1:0|O2:0|O1:0|O2:3|O1:0|O2:0|O1:0|O2:1|O1:0|O2:0,Fluvoxamine|Placebo,Deterioration,Detection ,['Deterioration'],NA,4165276,Likert scale,Measurement,outcome_250
299,NCT04425850,Number of Infected Subjects,O1:131|O2:98,O1:0|O2:11,IVER+|IVER-,Infect,Infect,['Infect'],Time Frame: Day 0-14 ,45885195,Infection,Meas Value,outcome_251
300,NCT04425850,Adverse Events Other Than Those Resulting From Contagion or Disease Progression,O1:131|O2:98,O1:0|O2:0,IVER+|IVER-,Adverse Events,Adverse,"['Adverse Events', 'Disease Progression', 'Adverse', 'Adverse Event', 'Progression']",Time Frame: From admission to 14 days after being discharge. ,45884383,Adverse event,Meas Value,outcome_252
301,NCT04411667,Mechanical Ventilation,O1:16|O2:17,O1:2|O2:7,Group A (Study Drug+SOC)|Group B (SOC),Mechanical Ventilation ,Mechanical Ventilation ,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",4230167,Artificial respiration,Procedure,outcome_69
302,NCT04411667,Oxygen Therapy,O1:0|O2:0,NA,Group A (Study Drug+SOC)|Group B (SOC),Oxygen Therapy ,Oxygen,"['Oxygen', 'Oxygen Therapy']",Time Frame: 28 days after randomization ,36311244,Oxygen therapy,Meas Value,outcome_253
303,NCT04411667,Length of Stay,O1:16|O2:17,O1:12|O2:17,Group A (Study Drug+SOC)|Group B (SOC),Length of Stay ,Length of Stay ,['Length of Stay'],Require Mechanical Ventilation,46236995,Hospital stay duration,Observation,outcome_254
304,NCT04698993,Sensitivity,O1:264|O2:0,O1:96.7,Symptomatic|Asymptomatic,Sensitivity,Sensitivity,[],NA,4148702,Sensitivity,Condition,outcome_255
305,NCT04698993,Specificity,O1:264|O2:0,O1:99.5,Symptomatic|Asymptomatic,Specificity,Specificity,[],NA,4320344,Specific,Observation,outcome_256
306,NCT04698993,Sensitivity in Relation to the Cycle Threshold Value of the Reference RT-PCR (in the Symptomatic Group),O1:69|O2:0,O1:97.8,Symptomatic|Asymptomatic,Symptom,Symptom,"['Symptom', 'RT-PCR']",NA,35939556,"Negative/normal, RT-PCR test",Meas Value,outcome_257
307,NCT04698993,Sensitivity in Relation to the Time Since Symptom Onset (in the Symptomatic Group),O1:69|O2:0,O1:90.9,Symptomatic|Asymptomatic,Symptom,Symptom,['Symptom'],NA,4226277,Time of symptom onset,Observation,outcome_258
308,NCT04698993,Specificity in Asymptomatic Participants,O1:0|O2:105,O2:100,Symptomatic|Asymptomatic,Symptom,Symptom,['Symptom'],NA,45881176,Asymptomatic,Meas Value,outcome_259
309,NCT04698993,Frequency of Nosebleed or Unbearable Pain During or Immediately After Specimen Collection,O1:275|O2:113,O1:0|O2:0,Symptomatic|Asymptomatic,Pain,Pain,[],NA,45881352,Pain,Meas Value,outcome_260
310,NCT04502056,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention,O1:14999|O2:3763,O1:0.214|O2:0.241,Intervention|Control,Incidence Rate,Incidence Rate,[],NA,44803958,Knowledge,Observation,outcome_261
311,NCT04502056,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention - Follow up,O1:4819|O2:1211,O1:0.241|O2:0.250,Intervention|Control,Incidence Rate,Incidence Rate,[],NA,44803958,Knowledge,Observation,outcome_261
312,NCT04502056,Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention,O1:14569|O2:3654,O1:0.338|O2:0.320,Intervention|Control,Incidence Rate,Incidence Rate,[],NA,NA,Incidence Rate,NA,outcome_262
313,NCT04502056,Incidence Rate - Safety Gap Score: Control vs. Any Intervention,O1:4823|O2:1212,O1:0.450|O2:0.465,Intervention|Control,Incidence Rate,Incidence Rate,[],NA,45880179,Safety,Meas Value,outcome_263
314,NCT04502056,Willingness to Pay (WTP) for Masks: Control vs. Any Intervention,O1:13399|O2:3360,O1:14.580|O2:14.072,Intervention|Control,Willingness to Pay (WTP) for Masks,WTP,[],NA,4130245,Mask,Device,outcome_264
315,NCT04502056,Incidence Rate Ratio (IRR) - Knowledge Gap,O1:18762|O2:18762|O3:18762|O4:18762|O5:18762|O6:18762,O1:1.01|O2:0.99|O3:1.01|O4:0.99|O5:0.99|O6:0.89,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,[],NA,44803958,Knowledge,Observation,outcome_265
316,NCT04502056,Incidence Rate Ratio (IRR) - Knowledge Gap - Follow up,O1:6030|O2:6030|O3:6030|O4:6030|O5:6030|O6:6030,O1:0.98|O2:0.98|O3:1.01|O4:1.01|O5:0.98|O6:0.97,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,[],NA,44803958,Knowledge,Observation,outcome_265
317,NCT04502056,Incidence Rate Ratio (IRR) - Information-seeking Behavior,O1:18223|O2:18223|O3:18223|O4:18223|O5:18223|O6:18223,O1:1.04|O2:1.03|O3:1.02|O4:0.96|O5:0.97|O6:1.01,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,[],NA,44803685,Information,Observation,outcome_266
318,NCT04502056,Incidence Rate Ratio (IRR) - Safety Gap Score,O1:6035|O2:6035|O3:6035|O4:6035|O5:6035|O6:6035,O1:1.04|O2:1.03|O3:1.01|O4:0.97|O5:0.95|O6:0.93,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Incidence Rate Ratio (IRR),IRR,[],NA,45880179,Safety,Meas Value,outcome_267
319,NCT04502056,OLS Regression Coefficients - Willingness to Pay (WTP) for Masks,O1:16759|O2:16759|O3:16759|O4:16759|O5:16759|O6:16759,O1:-0.21|O2:-0.29|O3:0.07|O4:0.17|O5:0.32|O6:0.71,Within Intervention Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Intervention Group: AMA Anti-racism (Arm A) vs. Either/Neither (Arm B)|Within Intervention Group: Doctor Racial Disparity (Arm A) vs. Either/Neither (Arm B)|Within Control Group: Black Physician (Arm A) vs. White Physician (Arm B)|Within Control Group: AMA Anti-racism vs. Either/Neither|Intervention Group vs. Control Group,Willingness to Pay (WTP) for Masks,WTP,[],NA,4130245,Mask,Device,outcome_264
320,NCT04491994,Number of Participants With Progression,O1:151|O2:349,O1:5|O2:11,Standard of Care (SOC)|Intervention Group,Progression ,Progression ,['Progression'],Time Frame: 14 days ,4090959,Progressing to,Observation,outcome_268
321,NCT04491994,Viral Clearance,NA,NA,NA,Viral Clearance ,Viral Clearance,['Viral Clearance'],Time Frame: Pre-SSI ,4124760,Clearance,Observation,outcome_144
322,NCT04728802,14 Day Recovery Rate,O1:317|O2:328,O1:258|O2:117,Proxalutamide + Usual Care|Placebo + Usual Care,Recovery,Recovery,['Recovery'],Time Frame: Baseline to Day 29 ,37079031,Partial recovery,Meas Value,outcome_269
323,NCT04728802,28 Day Recovery Rate,O1:317|O2:328,O1:271|O2:155,Proxalutamide + Usual Care|Placebo + Usual Care,Recovery,Recovery,['Recovery'],Time Frame: Day 29 ,45757484,Every twenty eight days,Observation,outcome_270
324,NCT04728802,28 Day Mortality Rate,O1:317|O2:328,O1:35|O2:162,Proxalutamide + Usual Care|Placebo + Usual Care,Mortality,Death ,"['Mortality Rate', 'Mortality']",Time Frame: during the survey administration ,4249566,Mortality rate,Observation,outcome_222
325,NCT04728802,Post-Randomization Time to Recover (Alive Hospital Discharge),O1:317|O2:328,O1:5|O2:10,Proxalutamide + Usual Care|Placebo + Usual Care,discharge,Discharge,"['discharge', 'Discharge', 'Alive', 'Hospital']",Time Frame: Day 1 through Day 29 ,31999,Recovered,Cost,outcome_271
326,NCT04422561,"Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)",O1:203|O2:101,O1:15|O2:59,Ivermectin Group|Control Group,Fever ,Fever ,"['Development', 'Symptom', 'Fever']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",46234710,Symptom,Observation,outcome_272
327,NCT04422561,Development of COVID,NA,NA,NA,Development,Development,['Development'],Time Frame: Day 5 ,4162085,Development of care plan,Procedure,outcome_273
328,NCT04356937,Mechanical Ventilation or Death,O1:161|O2:81,O1:9.9|O2:10.0|O1:10.6|O2:12.5,Tocilizumab|Placebo,Death,Death ,"['mechanical Ventilation', 'Mechanical Ventilation', 'Death']",NA,4230167|4306655,Artificial respiration|Death,Procedure|Observation,outcome_274
329,NCT04356937,Clinical Worsening on Ordinal Scale,O1:161|O2:81,O1:18.0|O2:14.9|O1:19.3|O2:17.4,Tocilizumab|Placebo,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'ordinal scale']",NA,4332312,Worsening,Observation,outcome_275
330,NCT04356937,Discontinuation of Supplemental Oxygen Among Patients Receiving it at Baseline,O1:138|O2:66,O1:75.4|O2:78.8|O1:82.6|O2:84.9,Tocilizumab|Placebo,Oxygen,Oxygen,['Oxygen'],NA,45884194,Receiving supplemental oxygen,Meas Value,outcome_276
331,NCT04407507,Participants With a Disease Control Status Defined as no Disease Progression to Severe.,O1:30|O2:26,O1:30|O2:26,Ivermectin|Placebo,Disease Progression,Progression,"['Disease Progression', 'Progression']",Time Frame: Day 1 through Day 29 ,4128759,Under care of radiologist,Observation,outcome_277
332,NCT04407507,"SARS-CoV-2 Viral Load, at 5 and 14 Days",O1:30|O2:26|O1:30|O2:26|O1:26|O2:24|O1:21|O2:20,O1:26.17|O2:23.3|O1:30.52|O2:28.5|O1:33.74|O2:32.94,Ivermectin|Placebo|Ivermectin|Placebo|Ivermectin|Placebo|Ivermectin|Placebo,Viral Load ,Viral Load,['Viral Load'],Time Frame: Immediately Post-SSI only ,37311065,SARS-CoV-2,Observation,outcome_278
333,NCT04407507,Presence and Frequency of Symptoms Associated With the COVID-19 Disease,O1:30|O2:26,O1:7.67|O2:5.44|O1:51.7|O2:34.1|O1:29.5|O2:24.6|O1:45.4|O2:38.1|O1:16.7|O2:14.9|O1:32.3|O2:26.9|O1:13|O2:9.74|O1:25.7|O2:17.5|O1:13|O2:7.16|O1:18.9|O2:8.31|O1:19.4|O2:10.9|O1:1.79|O2:0.57|O1:28.6|O2:14.3,Ivermectin|Placebo,Symptom,Symptom,['Symptom'],Time Frame: Approximately 30 days ,1333343,COVID-19 Related Symptoms,Observation,outcome_279
334,NCT04390022,Proportion of Patients With a Positive SARS-CoV-2 PCR,O1:12|O2:12,O1:12|O2:12|O1:11|O2:12,Ivermectin|Placebo,Positive,Positive,['Positive'],Time Frame: 14 days ,3667069,Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction,Observation,outcome_280
335,NCT04390022,Median Viral Load,O1:12|O2:12,O1:16850000|O2:26700000|O1:161000|O2:493500|O1:1018|O2:23550|O1:7|O2:30|O1:1|O2:0|O1:367000000|O2:327500000|O1:269000|O2:2194500|O1:2255|O2:36800|O1:86|O2:75|O1:0|O2:107,Ivermectin|Placebo,Viral Load ,Viral Load,['Viral Load'],Time Frame: Pre-SSI only ,37393279,Viral load,Measurement,outcome_281
336,NCT04390022,Fever and Cough Progression,O1:12|O2:12,O1:0|O2:0|O1:1|O2:0|O1:0|O2:0|O1:0|O2:0|O1:5|O2:6|O1:5|O2:5|O1:1|O2:3|O1:1|O2:3,Ivermectin|Placebo,Fever ,Fever ,"['Fever', 'Progression']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4048098,Cough with fever,Condition,outcome_282
337,NCT04390022,Seroconversion at Day 21,O1:12|O2:12,O1:12|O2:12,Ivermectin|Placebo,Seroconversion at Day 21 ,Seroconversion,['Seroconversion at Day 21'],Time Frame: Baseline up to 60 days ,4153902,Conversions,Observation,outcome_283
338,NCT04390022,Proportion of Drug-related Adverse Events,O1:12|O2:12,O1:0|O2:0,Ivermectin|Placebo,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. ,45884383,Adverse event,Meas Value,outcome_174
339,NCT04390022,"Levels of IgG, IgM and IgA",NA,NA,NA,IgG,IgG,['IgG'],Time Frame: 28 Days ,36308963,IgM and IgG positive,Meas Value,outcome_284
340,NCT04390022,Frequency of Innate Immune Cells,NA,NA,NA,Innate Immune Cells ,Innate Immune Cells ,['Innate Immune Cells'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) ",4275284,Immunologic cell,Spec Anatomic Site,outcome_285
341,NCT04390022,Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells,NA,NA,NA,CD4+,CD4+,['CD4+'],Time Frame: Baseline ,3020073,CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Specimen,Measurement,outcome_286
342,NCT04390022,Results From Cytokine Human Magnetic 30-Plex Panel,NA,NA,NA,Cytokine Human Magnetic 30-Plex Panel ,Cytokine Human Magnetic 30-Plex Panel ,['Cytokine Human Magnetic 30-Plex Panel'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4049969,Cytokinesis,Observation,outcome_287
343,NCT04409886,Oxygenation Index,O1:0,NA,HBOT (Hyperbaric Oxygen Therapy),Oxygen,Oxygen,['Oxygen'],NA,37393330,Oxygenation index,Measurement,outcome_288
344,NCT04399980,Subjects Alive and Off of Oxygen at Day 14,O1:21|O2:19,O1:12|O2:9,Intervention|Control,Off of Oxygen at Day 14 ,Oxygen,"['Oxygen', 'Alive', 'Off of Oxygen at Day 14']",Time Frame: Day 30 ,19025274,oxygen,Drug,outcome_289
345,NCT04399980,Number of Subjects Alive and Without Respiratory Failure at Day 28,O1:21|O2:19,O1:20|O2:15,Intervention|Control,Without Respiratory Failure at Day 28,Without Respiratory Failure,"['Without Respiratory Failure at Day 28', 'Alive']",Time Frame: 0 to 24 hours post dose ,36311042,Respiratory failure,Meas Value,outcome_290
346,NCT04399980,Mortality at Day 28,O1:21|O2:19,O1:1|O2:3,Intervention|Control,Mortality,Death ,['Mortality'],Time Frame: 7 days post-treatment ,4249566,Mortality rate,Observation,outcome_291
347,NCT04365153,Number of Participants With Clinical Improvement at Day 14,O1:15|O2:14|O3:16,O1:9|O2:7|O3:9,High Dose Intervention|Low Dose Intervention|Control,Improvement,Improvement,"['improvement', 'Improvement']",Time Frame: Day 14 ,4308350,Improvement of status,Observation,outcome_219
348,NCT04365153,All-cause Mortality,O1:15|O2:14|O3:16,O1:1|O2:3|O3:3,High Dose Intervention|Low Dose Intervention|Control,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 21 ,36031791,All-cause deaths since start of event,Measurement,outcome_292
349,NCT04365153,NA,NA,NA,NA,nan,nan,['nan'],NA,NA,NA,NA,outcome_197
350,NCT04491240,Number of Participants With Non-serious and Serious Adverse Events During Trial,O1:10|O2:10|O3:10,O1:0|O2:0|O3:0|O1:0|O2:0|O3:0,EXO-1|EXO-2|Placebo,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: Admission to discharge dates (approximately 4-14 days after admission). Discharge variables considered as the last available data before their death for the expired patients. ,45884383,Adverse event,Meas Value,outcome_174
351,NCT04491240,Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure,O1:10|O2:10|O3:10,O1:0|O2:0|O3:0|O1:0|O2:0|O3:0|O1:0|O2:0|O3:0|O1:0|O2:0|O3:0,EXO-1|EXO-2|Placebo,Adverse,Adverse,['Adverse'],Time Frame: Day 1 to end-of-trial (Visit 9) ,45884383,Adverse event,Meas Value,outcome_293
352,NCT04491240,Time to Clinical Recovery (TTCR),O1:10|O2:10|O3:10,O1:13.8|O2:14.8|O3:14.1,EXO-1|EXO-2|Placebo,Recovery,Recovery,['Recovery'],"Time Frame: Baseline, Days 4, 7, 15, 21, and 29 ",31999,Recovered,Cost,outcome_294
353,NCT04491240,C-reactive Protein,O1:10|O2:10|O3:10,O1:78.3|O2:75.4|O3:61.5|O1:5.04|O2:5.83|O3:8.29,EXO-1|EXO-2|Placebo,C-reactive Protein ,CRP,['C-reactive Protein'],Time Frame: 14 days ,4052151,C-reactive protein reaction,Observation,outcome_295
354,NCT04491240,C-reactive Protein,NA,NA,NA,C-reactive Protein ,CRP,['C-reactive Protein'],Time Frame: 14 days ,4052151,C-reactive protein reaction,Observation,outcome_295
355,NCT04491240,C-reactive Protein,NA,NA,NA,C-reactive Protein ,CRP,['C-reactive Protein'],Time Frame: 14 days ,4052151,C-reactive protein reaction,Observation,outcome_295
356,NCT04491240,Lactic Acid Dehydrogenase (LDH),O1:10|O2:10|O3:10,O1:773|O2:732|O3:669|O1:441|O2:365|O3:430,EXO-1|EXO-2|Placebo,Lactic Acid Dehydrogenase (LDH) ,LDH,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days ,35917352,Lactate Dehydrogenase (LDH),Measurement,outcome_296
357,NCT04491240,Lactic Acid Dehydrogenase (LDH),NA,NA,NA,Lactic Acid Dehydrogenase (LDH) ,LDH,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days ,35917352,Lactate Dehydrogenase (LDH),Measurement,outcome_296
358,NCT04491240,Lactic Acid Dehydrogenase (LDH),NA,NA,NA,Lactic Acid Dehydrogenase (LDH) ,LDH,"['LDH', 'Lactic Acid Dehydrogenase (LDH)']",Time Frame: First dose date up to last dose date (maximum: 10 days) plus 30 days ,35917352,Lactate Dehydrogenase (LDH),Measurement,outcome_296
359,NCT04335552,World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment,O1:1|O2:4|O3:3|O4:2,O1:1|O2:2.5|O3:5.3|O4:4.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'ordinal scale']",NA,4062806,Scale,Device,outcome_297
360,NCT04335552,Number of Participants Who Died During the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:2|O4:1,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Died,Death ,"['Hospitalization', 'hospitalization', 'Hospital']",NA,1314487,Death occurring during the index acute care hospitalization,Observation,outcome_298
361,NCT04335552,Number of Days on Mechanical Ventilation,O1:1|O2:4|O3:3|O4:2,O1:0|O2:5.5|O3:8.67|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']",NA,4230167,Artificial respiration,Procedure,outcome_138
362,NCT04335552,Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:1|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Mechanical Ventilation,Mechanical Ventilation,"['Hospitalization', 'mechanical Ventilation', 'Mechanical Ventilation', 'hospitalization', 'Hospital']",NA,4230167,Artificial respiration,Procedure,outcome_138
363,NCT04335552,WHO Ordinal Scale Measured at 28 Days After Enrollment,O1:1|O2:4|O3:3|O4:2,O1:1|O2:2.8|O3:5.3|O4:4.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'ordinal scale']",NA,2719865|4062806,WHO|Scale,Device|Device,outcome_299
364,NCT04335552,Hospital Length of Stay in Days for the Index Hospitalization,O1:1|O2:4|O3:3|O4:2,O1:6|O2:9|O3:14.7|O4:2.5,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Hospitalization,Hospitalization,"['Length of Stay', 'Hospitalization', 'hospitalization', 'Hospital']",NA,46236995,Hospital stay duration,Observation,outcome_300
365,NCT04335552,Number of Participants With All-cause Study Medication Discontinuation,O1:1|O2:4|O3:3|O4:2,O1:0|O2:0|O3:0|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Number,Number,[],NA,36309075,Discontinue,Meas Value,outcome_301
366,NCT04335552,Number of Participants With Severe Adverse Events,O1:1|O2:4|O3:3|O4:2,O1:0|O2:1|O3:1|O4:0,Standard of Care|Standard of Care Plus Hydroxychloroquine|Standard of Care Plus Azithromycin|Standard of Care Plus Hydroxychloroquine Plus Azithromycin,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,45884383,Adverse event,Meas Value,outcome_199
367,NCT04898166,Androgenetic Alopecia Frequency in Participants.,O1:220|O2:80,O1:209|O2:37|O1:11|O2:43,220 Hospitalized Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,4339092,Male pattern alopecia,Condition,outcome_302
368,NCT04898166,Severity of Androgenetic Alopecia in Patients,O1:220|O2:37,O1:43|O2:9|O1:177|O2:28,220 Hospitalised Male Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,4339092,Male pattern alopecia,Condition,outcome_302
369,NCT04898166,300 Participants Mean Age,O1:300,O1:53.06,300 Participants Diagnosed Case of Hospitalized COVID-19. Mean Age be Noted,Age,Age,[],NA,4265453,Age,Observation,outcome_303
370,NCT04898166,Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.,O1:220|O2:80,O1:15|O2:10|O1:13|O2:18|O1:13|O2:0|O1:15|O2:4|O1:37|O2:12|O1:20|O2:0|O1:4|O2:11|O1:16|O2:15|O1:10|O2:0|O1:7|O2:4|O1:33|O2:6|O1:37|O2:0,220 Hospitalised Male Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,37020968,Disease outcome [Type],Observation,outcome_304
371,NCT04898166,Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males,O1:220,O1:20|O1:52|O1:14|O1:27|O1:5|O1:25|O1:4|O1:73,220 Hospitalised Male Subjects. Their Disease Outcomes in Relation to Severity of AGA,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,37020968,Disease outcome [Type],Observation,outcome_304
372,NCT04898166,Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females,O1:80,O1:9|O1:3|O1:4|O1:17|O1:3|O1:8|O1:14|O1:3|O1:9|O1:3|O1:0|O1:7,80 Hospitalised Female Participants. Their Disease Outcomes in Relation to Severity of AGA,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,4339092,Male pattern alopecia,Condition,outcome_302
373,NCT04898166,Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.,O1:37|O2:43,O1:0|O2:4|O1:7|O2:5|O1:00|O2:00|O1:3|O2:7|O1:8|O2:10|O1:00|O2:00|O1:6|O2:5|O1:6|O2:9|O1:00|O2:00|O1:3|O2:1|O1:4|O2:2|O1:00|O2:00,37 Hospitalised Female Participants of COVID-19 With Androgenetic Alopecia|43 Hospitalised Female Participants of COVID-19 Without Androgenetic Alopecia With Respect to Age,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,37020968,Disease outcome [Type],Observation,outcome_304
374,NCT04898166,Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males,O1:43|O2:177,O1:4|O2:11|O1:10|O2:27|O1:6|O2:14|O1:6|O2:9|O1:5|O2:8|O1:3|O2:10|O1:1|O2:3|O1:2|O2:14|O1:2|O2:8|O1:0|O2:7|O1:1|O2:32|O1:3|O2:34,43 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS <3.|177 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS >3-7,Androgenetic Alopecia,Androgenetic Alopecia,[],NA,37020968,Disease outcome [Type],Observation,outcome_304
375,NCT04898166,Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females,O1:220|O2:80,O1:41|O2:28|O1:72|O2:16|O1:30|O2:26|O1:77|O2:10,220 Hospitalized Participants Diagnosed Case of COVID-19.|80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19,Hospitalization,Hospitalization,['Hospital'],NA,37020968,Disease outcome [Type],Observation,outcome_305
376,NCT04898166,"Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants",O1:300,O1:29|O1:6|O1:4|O1:12|O1:15|O1:8|O1:5|O1:9|O1:20|O1:6|O1:1|O1:15|O1:8|O1:6|O1:4|O1:9|O1:17|O1:1|O1:2|O1:7|O1:10|O1:6|O1:1|O1:12|O1:26|O1:1|O1:9|O1:18|O1:18|O1:1|O1:5|O1:9,300 Participants Diagnosed Case of Hospitalized COVID-19 Outcome in Relation to Comorbidities,Comorbidities,Comorbidities,[],NA,4160039,Co-morbid conditions,Condition,outcome_306
377,NCT04898166,Disease Duration of COVID-19,O1:300,O1:11.79,300 Participants Diagnosed Case of Hospitalized COVID-19 Disease Duration,Disease Duration,Disease Duration,[],NA,37311061,COVID-19,Condition,outcome_307
378,NCT04475588,One-month Mortality Rate Between the Two Arms,O1:20|O2:10,O1:0|O2:3,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Mortality,Death ,"['Mortality Rate', 'Mortality']","Time Frame: Days 4, 7, 14 and 21 ",4249566,Mortality rate,Observation,outcome_308
379,NCT04475588,Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2,O1:20|O2:10,O1:17|O2:5|O1:19|O2:7|O1:20|O2:7|O1:20|O2:7,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),SpO2,SpO2,"['SpO2', 'Improved', 'Lung Function Assessment - Proportion']",Time Frame: Days 1 - 29 ,4052083,Measurement of respiratory function,Measurement,outcome_309
380,NCT04475588,Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV),O1:20|O2:10,O1:0|O2:2,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV) ,IMV,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV)']",Time Frame: Day 1 through Day 29 ,42530690,Invasive mechanical ventilation by intubation or tracheostomy,Meas Value,outcome_310
381,NCT04475588,Reduction in Proportion of Patients on Non-invasive Ventilation,O1:20|O2:10,O1:5|O2:4|O1:0|O2:0|O1:5|O2:1|O1:5|O2:1|O1:5|O2:1,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Reduction in Proportion of Patients on Non-invasive Ventilation ,Reduction in Proportion of Patients on Non-invasive Ventilation ,['Reduction in Proportion of Patients on Non-invasive Ventilation'],Time Frame: Baseline to Day 29 ,4177224,Noninvasive ventilation,Procedure,outcome_311
382,NCT04475588,Lung Function Assessment - Proportion of Patients With Stable PaO2 Without Increasing FiO2,O1:20|O2:10,O1:18|O2:6|O1:19|O2:7|O1:20|O2:7|O1:20|O2:7,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Lung Function Assessment - Proportion,Lung Function Assessment - Proportion,['Lung Function Assessment - Proportion'],"Time Frame: Baseline, Day 15, Day 29 ",4052083,Measurement of respiratory function,Measurement,outcome_312
383,NCT04475588,Reduction in Proportion of Patients- Invasive Mechanical Ventilation,O1:0|O2:0,NA,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Invasive Mechanical Ventilation ,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation']",Time Frame: Up to 28 days ,44790095,Invasive ventilation,Procedure,outcome_313
384,NCT04475588,Reduction in Proportion of Patients-High Flow Nasal Oxygen,O1:0|O2:0,NA,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),High Flow Nasal Oxygen ,High Flow Nasal Oxygen ,"['Oxygen', 'High Flow Nasal Oxygen']",Time Frame: Day 1 through Day 29 ,4139525,High flow oxygen nasal cannula,Device,outcome_314
385,NCT04475588,Mean Change From Baseline in Ferritin,O1:20|O2:10|O1:18|O2:7|O1:15|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-117.8|O2:-87.05|O1:-713.9|O2:-209.6|O1:-780.9|O2:4238|O1:-479.3|O2:-234.4,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Ferritin,Ferritin,"['Mean Change', 'Ferritin']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4176561,Ferritin measurement,Measurement,outcome_315
386,NCT04475588,Mean Change From Baseline in LDH,O1:20|O2:10|O1:18|O2:7|O1:15|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-134|O2:-44.29|O1:-195.8|O2:-195.2|O1:-308.1|O2:155.3|O1:-212.7|O2:-97,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),LDH,LDH,"['LDH', 'Mean Change']",Time Frame: Day 11 ,4139809,Changed status,Observation,outcome_316
387,NCT04475588,Mean Change From Baseline in CRP (C-reactive Protein),O1:20|O2:10|O1:18|O2:8|O1:16|O2:5|O1:11|O2:3|O1:3|O2:2,O1:-61.69|O2:-103.6|O1:-81.65|O2:-107.2|O1:-90.99|O2:-127.5|O1:-103.2|O2:-127.6,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),CRP (C-reactive Protein),CRP,"['C-reactive Protein', 'CRP (C-reactive Protein)', 'Mean Change']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4208414,C-reactive protein measurement,Measurement,outcome_110
388,NCT04475588,Mean Change From Baseline D-Dimer,O1:20|O2:10|O1:18|O2:7|O1:12|O2:4|O1:11|O2:2|O1:3|O2:2,O1:-1.43|O2:2.30|O1:-0.45|O2:-0.68|O1:-4.35|O2:8.54|O1:-2.63|O2:-0.35,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),D-dimer,D-dimer,"['D-dimer', 'Mean Change']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",37393605,D-dimer level,Measurement,outcome_317
389,NCT04475588,Mean Change From Baseline of Absolute Lymphocyte Count,O1:20|O2:10|O1:20|O2:8|O1:16|O2:5|O1:11|O2:3|O1:4|O2:2,O1:119.95|O2:45.88|O1:421.25|O2:142.60|O1:701.55|O2:10.00|O1:719.75|O2:85.00,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Lymphocyte Count,Lymphocyte Count,"['Mean Change', 'Lymphocyte Count']","Time Frame: Baseline, Day 15, Day 29 ",37393858,Lymphocyte count,Measurement,outcome_23
390,NCT04475588,"Biomarkers (IL-6, TNF-a)",O1:18|O2:10|O1:18|O2:10|O1:18|O2:10|O1:13|O2:4|O1:13|O2:4|O1:18|O2:10|O1:18|O2:10|O1:13|O2:4|O1:13|O2:4,O1:159.09|O2:162.16|O1:42.98|O2:211.52|O1:311.3|O2:310.4|O1:91.0|O2:316.8|O1:43.64|O2:11.26|O1:8.87|O2:39.19|O1:68.0|O2:107.8|O1:50.1|O2:185.0,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),TNF,TNF,"['TNF', 'IL-6']",Time Frame: Pre-SSI to 3-month follow-up ,4203714,Maker,Observation,outcome_318
391,NCT04475588,"Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio)",O1:20|O2:10|O1:20|O2:10|O1:16|O2:6|O1:14|O2:5|O1:8|O2:3|O1:3|O2:0,O1:126.57|O2:114.05|O1:203.50|O2:184.53|O1:283.43|O2:338.40|O1:350.25|O2:398.33|O1:397.67,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC)|Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),P/F Ratio,P/F Ratio,"['Oxygen', 'P/F Ratio']",Time Frame: 28 days after randomization ,4353936,Inspired oxygen concentration,Measurement,outcome_53
392,NCT04475588,Number and Percentage of Patients With Radiological Response,O1:20|O2:10,O1:9|O2:1,Arm A - Itolizumab + BSC|Arm B - Best Supportive Care (BSC),Radiological Response ,Radiological Response ,['Radiological Response'],Time Frame: 24 hours after the last 2000 U dose of the chronic phase ,4128759,Under care of radiologist,Observation,outcome_319
393,NCT04343261,Mortality,O1:41,O1:19,COVID-19 Patients Treated With Convalescent Plasma,Mortality,Death ,['Mortality'],"Time Frame: Baseline and on days 4, 7, 14 and 21 ",4249566,Mortality rate,Observation,outcome_320
394,NCT04343261,Viral Load,O1:35|O1:13|O1:9|O1:7|O1:4,O1:3524|O1:2033|O1:315|O1:494,COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma,Viral Load ,Viral Load,['Viral Load'],Time Frame: Pre-SSI only ,37393279,Viral load,Measurement,outcome_281
395,NCT04343261,Serum Antibody Titers,O1:39|O1:39|O1:36|O1:30|O1:24,O1:18.5|O1:37.2|O1:47.4|O1:55.2,COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma|COVID-19 Patients Treated With Convalescent Plasma,Serum Antibody Titers ,Antibody Titers,['Serum Antibody Titers'],Time Frame: Baseline up to 60 days ,4095027,Antibody titer measurement,Measurement,outcome_321
396,NCT04446429,COVID-19 Hospitalization,O1:134|O2:134,O1:35|O2:3,Usual Care|Proxalutamide + Usual Care,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 15 ,37311061|45884746,COVID-19|Hospitalization,Condition|Meas Value,outcome_322
397,NCT04446429,NA,NA,NA,NA,nan,nan,['nan'],NA,NA,NA,NA,outcome_197
398,NCT04332991,COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization),O1:242|O2:237,O1:6|O2:6,Hydroxychloroquine|Placebo,scale score,scale score,"['outcomes scale', 'scale score']",Time Frame: Baseline to Day 29 ,37397407,Outcome Rating Scale,Measurement,outcome_323
399,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization),O1:242|O2:237,O1:4|O2:4,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,['outcomes scale'],Time Frame: assessed on study day 29 ,37397407,Outcome Rating Scale,Measurement,outcome_324
400,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization),O1:242|O2:237,O1:5|O2:6,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,['outcomes scale'],Time Frame: assessed on study day 15 ,37397407,Outcome Rating Scale,Measurement,outcome_325
401,NCT04332991,COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization),O1:242|O2:237,O1:6|O2:6,Hydroxychloroquine|Placebo,outcomes scale,outcomes scale,['outcomes scale'],Time Frame: assessed on study day 29 ,37397407,Outcome Rating Scale,Measurement,outcome_324
402,NCT04332991,"All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)",O1:241|O2:236,O1:18|O2:14,Hydroxychloroquine|Placebo,Mortality,Death ,['Mortality'],Time Frame: 7 days post treatment ,4249566,Mortality rate,Observation,outcome_326
403,NCT04332991,"All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)",O1:241|O2:236,O1:25|O2:25,Hydroxychloroquine|Placebo,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
404,NCT04332991,Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28,O1:241|O2:236,O1:29|O2:28,Hydroxychloroquine|Placebo,ECMO,ECMO,['ECMO'],Time Frame: Day 1 through Day 15 ,1147312|45878735,death|ECMO,Metadata|Meas Value,outcome_327
405,NCT04332991,Oxygen-free Days Through Day 28,O1:242|O2:237,O1:21|O2:20,Hydroxychloroquine|Placebo,Oxygen-free,Oxygen,"['Oxygen', 'Oxygen-free']",Time Frame: 28 days after randomization ,36310094,No supplemental oxygen,Meas Value,outcome_328
406,NCT04332991,Ventilator-free Days Through Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,Ventilator-free,Ventilator-free,['Ventilator-free'],Time Frame: Pre-SSI only ,44786857,Days on ventilator,Measurement,outcome_329
407,NCT04332991,Vasopressor-free Days Through Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,Vasopressor-free,Vasopressor-free,['Vasopressor-free'],Time Frame: Pre-SSI only ,3655896,Vasopressor therapy,Procedure,outcome_330
408,NCT04332991,ICU-free Days to Day 28,O1:242|O2:237,O1:28|O2:28,Hydroxychloroquine|Placebo,ICU-free,ICU,"['ICU-free', 'ICU']",Time Frame: 28 Days ,44786856,Days in intensive care unit,Observation,outcome_331
409,NCT04332991,Hospital-free Days to Day 28,O1:242|O2:237,O1:21|O2:20,Hydroxychloroquine|Placebo,Hospital-free,Hospitalization,"['Hospital', 'Hospital-free']",Time Frame: Day 5 ,4202182,Referral to day hospital,Observation,outcome_332
410,NCT04385238,Number of Participants With Symptoms of Post-traumatic Stress Disorder,O1:5712|O2:1182,O1:1028|O2:532,Pregnant Women|Post-partum Women,Post-traumatic Stress Disorder ,PTSD,"['Symptom', 'Post-traumatic Stress Disorder']",Time Frame: 30 days ,436676,Posttraumatic stress disorder,Condition,outcome_333
411,NCT04385238,Number of Participants With Symptoms of Anxiety and Depression,O1:5712|O2:1182,O1:1200|O2:438,Pregnant Women|Post-partum Women,"Anxiety, Depression ","Anxiety, Depression ",['Symptom'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) ,4191716,Symptoms of depression,Condition,outcome_334
412,NCT04370834,Number of Participants With at Least 1 Point Reduction in Score on 7-category Clinical Status Ordinal Scale,O1:1|O2:0|O3:0|O4:0,O1:1,Cohort A1|Cohort A2|Cohort B1|Cohort B2,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",NA,4138597,Clinical status,Observation,outcome_176
413,NCT04323592,"Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28",O1:83|O2:90,O1:19|O2:40,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Invasive Mechanical Ventilation ,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation', 'Death', 'ICU']",Time Frame: 28 days ,44790095,Invasive ventilation,Procedure,outcome_335
414,NCT04323592,In-hospital Death Within 28 Days,O1:83|O2:90,O1:6|O2:21,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Hospital,Hospitalization,"['Death', 'Hospital']","Time Frame: Day 1, 3, 5, 8, 11, 15, 22, and 29 ",4061268,Death in hospital,Observation,outcome_336
415,NCT04323592,Admission to Intensive Care Unit (ICU),O1:83|O2:90,O1:15|O2:27,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Intensive Care,Intensive Care,"['Intensive Care', 'ICU']","Time Frame: baseline, day 14 ",45877945,Admission to intensive care unit,Meas Value,outcome_337
416,NCT04323592,Endotracheal Intubation (Invasive Mechanical Ventilation),O1:83|O2:90,O1:15|O2:26,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,Invasive Mechanical Ventilation ,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation', 'Invasive Mechanical Ventilation']",Time Frame: Day 14 ,4013354,Insertion of endotracheal tube,Procedure,outcome_338
417,NCT04323592,Change in C-reactive Protein (CRP),O1:83|O2:90,O1:-82.08|O2:-34.34,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,C-reactive Protein (CRP),CRP,"['C-reactive Protein (CRP)', 'C-reactive Protein']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4208414,C-reactive protein measurement,Measurement,outcome_110
418,NCT04323592,Number of Days Free From Mechanical Ventilation,O1:83|O2:90,O1:19.11|O2:14.34,Exposed to Methylprednisolone|Non-exposed to Methylprednisolone,mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Baseline, Day 15, Day 29 ",4230167,Artificial respiration,Procedure,outcome_339
419,NCT04371419,Incidence Rate for Knowledge Gaps: Control vs. Any Intervention,O1:1525|O2:10711,O1:0.085|O2:0.065,Study Participants - Control|Study Participants - Any Intervention,Incidence Rate,Incidence Rate,[],NA,44803958,Knowledge,Observation,outcome_261
420,NCT04371419,Incidence Rate for Information-seeking Behavior: Control vs. Any Intervention,O1:1450|O2:10244,O1:0.335|O2:0.344,Study Participants - Control|Study Participants - Any Intervention,Incidence Rate,Incidence Rate,[],NA,NA,Incidence Rate,NA,outcome_262
421,NCT04371419,Incidence Rate for Knowledge Gaps by Intervention,O1:5395|O2:5316|O3:8041|O4:2670|O5:8010|O6:2701|O7:8058|O8:2653|O9:5366|O10:5345,O1:0.066|O2:0.065|O3:0.065|O4:0.068|O5:0.066|O6:0.063|O7:0.066|O8:0.063|O9:0.066|O10:0.065,Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Discordant (Arm A)|Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Concordant (Arm B)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - MGH Physician (Arm A)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - Dr. Birx of the CDC (Arm B)|Intervention 3: Received Acknowledgment of Discrimination - No (Arm A)|Intervention 3: Received Acknowledgment of Discrimination - Yes (Arm B)|Intervention 4: Received Acknowledgment of Economic Inequalities - No (Arm A)|Intervention 4: Received Acknowledgment of Economic Inequalities - Yes (Arm B)|Intervention 5: Received Information About Social Perception - No (Arm A)|Intervention 5: Received Information About Social Perception - Yes (Arm B),Incidence Rate,Incidence Rate,[],NA,44803958,Knowledge,Observation,outcome_261
422,NCT04371419,Incidence Rate for Information-seeking Behavior by Intervention,O1:5147|O2:5097|O3:7697|O4:2547|O5:7653|O6:2591|O7:7696|O8:2548|O9:5142|O10:5102,O1:0.336|O2:0.353|O3:0.343|O4:0.348|O5:0.346|O6:0.341|O7:0.344|O8:0.345|O9:0.345|O10:0.344,Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Discordant (Arm A)|Intervention 1: Racial Discordance/Concordance Between Physician and Participant-Concordant (Arm B)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - MGH Physician (Arm A)|Intervention 2: Video 2 Recorded by MGH Physician/Dr. Birx of the CDC - Dr. Birx of the CDC (Arm B)|Intervention 3: Received Acknowledgment of Discrimination - No (Arm A)|Intervention 3: Received Acknowledgment of Discrimination - Yes (Arm B)|Intervention 4: Received Acknowledgment of Economic Inequalities - No (Arm A)|Intervention 4: Received Acknowledgment of Economic Inequalities - Yes (Arm B)|Intervention 5: Received Information About Social Perception - No (Arm A)|Intervention 5: Received Information About Social Perception - Yes (Arm B),Incidence Rate,Incidence Rate,[],NA,4092398,Attention seeking behavior,Condition,outcome_340
423,NCT04402970,Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2),O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:10|O2:20|O1:8|O2:20|O1:5|O2:11,O1:10.7|O2:21.4|O1:61.1|O2:11.8|O1:23.5|O2:12.5|O1:24.1|O2:3.5|O1:37.6|O2:5|O1:55|O2:-11.2,Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care,PaO2/FiO2,P/F Ratio,"['Oxygen', 'PaO2/FiO2']",Time Frame: 28 days after randomization ,4353936,Inspired oxygen concentration,Measurement,outcome_53
424,NCT04402970,Change in Static Lung Compliance,O1:10|O2:20|O1:10|O2:16|O1:10|O2:15|O1:8|O2:16|O1:8|O2:15|O1:5|O2:12|O1:4|O2:6,O1:3.1|O2:-0.1|O1:4|O2:-0.4|O1:6.3|O2:-5.7|O1:4|O2:-5.6|O1:7.4|O2:-4.8|O1:0.8|O2:-10.2,Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care|Inhaled/Nebulized Dornase Alfa|Standard of Care,Static Lung Compliance,Lung Compliance,['Static Lung Compliance'],Time Frame: Days 1 - 29. ,4090322,Static lung compliance,Measurement,outcome_341
425,NCT04402970,Duration of Mechanical Ventilation,O1:10|O2:20,O1:15.2|O2:18.2,Inhaled/Nebulized Dornase Alfa|Standard of Care,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']",Time Frame: 29 days ,4230167,Artificial respiration,Procedure,outcome_342
426,NCT04402970,Length of ICU Stay,O1:10|O2:20,O1:16.5|O2:22.1,Inhaled/Nebulized Dornase Alfa|Standard of Care,ICU,ICU,['ICU'],Time Frame: 28 days ,764528,Post intensive care unit syndrome,Condition,outcome_343
427,NCT04402970,Length of Hospitalization,O1:10|O2:20,O1:22.5|O2:28.7,Inhaled/Nebulized Dornase Alfa|Standard of Care,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 ,46236995,Hospital stay duration,Observation,outcome_22
428,NCT04402970,Secondary Bacterial Infections,O1:10|O2:20,O1:30|O2:25,Inhaled/Nebulized Dornase Alfa|Standard of Care,Infect,Infect,['Infect'],Time Frame: Day 0-14 ,4131056,Secondary infection,Condition,outcome_344
429,NCT04402970,Mortality,O1:10|O2:20,O1:40|O2:45|O1:40|O2:55,Inhaled/Nebulized Dornase Alfa|Standard of Care,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
430,NCT04328467,COVID-19-free Survival,O1:494|O2:495|O3:494,O1:464|O2:468|O3:454,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Survival,Survival,[],NA,37311061,COVID-19,Condition,outcome_345
431,NCT04328467,Number of Confirmed SARS-CoV-2 Detection,O1:494|O2:495|O3:494,O1:29|O2:29|O3:39,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Detection,Detection ,['Detection'],NA,320651,Severe acute respiratory syndrome,Condition,outcome_346
432,NCT04328467,Incidence of Possible COVID-19 Symptoms,O1:494|O2:495|O3:494,O1:29|O2:28|O3:38,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Symptom,Symptom,['Symptom'],NA,1333343,COVID-19 Related Symptoms,Observation,outcome_201
433,NCT04328467,Incidence of All-cause Study Medicine Discontinuation,O1:494|O2:495|O3:494,O1:119|O2:158|O3:133,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Medicine Discontinuation,Medicine Discontinuation,['Medicine Discontinuation'],NA,45882884,Medicine,Meas Value,outcome_347
434,NCT04328467,Ordinal Scale of COVID-19 Disease Maximum Severity if COVID-19 Diagnosed at Study End,O1:0|O2:1|O3:1,O2:1|O3:1,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Ordinal Scale,Ordinal Scale,"['Ordinal Scale', 'ordinal scale']",NA,703443,COVID-19 severity scale,Measurement,outcome_348
435,NCT04328467,Incidence of Hospitalization for COVID-19 or Death,O1:494|O2:495|O3:494,O1:3|O2:8|O3:9,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Hospitalization/Death,Hospitalization/Death,"['Hospitalization', 'Death', 'hospitalization', 'Hospital']",NA,36033654,COVID-19 Immunization note,Observation,outcome_349
436,NCT04328467,Incidence of Possible Study Medication-related Side Effects,O1:494|O2:495|O3:494,O1:148|O2:168|O3:100,Intervention Once Weekly|Intervention Twice Weekly|Control Group,Effect,Effect,['Effect'],NA,4288386,Assessment of adverse drug reactions,Procedure,outcome_350
437,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3178|O2:3198|O3:3190,O1:101|O2:207|O3:220,Delayed Contact|Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,[],NA,4144375,Active immunization,Procedure,outcome_351
438,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3198|O2:3190,O1:1481|O2:1398,Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,[],NA,4144375,Active immunization,Procedure,outcome_351
439,NCT04728594,Number of Employees Who Scheduled Vaccination Appointments After 3 Days,O1:3198|O2:3190,O1:562|O2:382,Social Proof|Reframing Side Effects and Adverse Reactions,Employees,Employees,[],NA,4144375,Active immunization,Procedure,outcome_351
440,NCT04728594,Number of Employees Who Opened Emails After 3 Days,NA,NA,NA,Employees,Employees,[],NA,4076484,Employee,Observation,outcome_352
441,NCT04728594,Number of Employees Who Clicked Scheduling Links After 3 Days,NA,NA,NA,Employees,Employees,[],NA,4076484,Employee,Observation,outcome_352
442,NCT04425863,Patients Who Improved Their Condition or Did Not Worsen it,O1:135|O2:12|O3:20,O1:135|O2:12|O3:19,Mild Cases|Moderate Cases|Severe Cases,Improved,Improvement,['Improved'],Time Frame: 28 day post enrollment ,45883510,Condition improved,Meas Value,outcome_353
443,NCT04425863,ICU-treated Patients After 2-week Treatment,O1:135|O2:12|O3:20,O1:0|O2:0|O3:2,Mild Cases|Moderate Cases|Severe Cases,ICU,ICU,['ICU'],Time Frame: 10 days ,4148981|40770080,Intensive care unit|Treatment duration,Observation|Observation,outcome_354
444,NCT04425863,Mortality,O1:135|O2:12|O3:20,O1:0|O2:0|O3:1,Mild Cases|Moderate Cases|Severe Cases,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
445,NCT04425863,Mortality,NA,NA,NA,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
446,NCT04425863,Mortality,NA,NA,NA,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 28 ,4249566,Mortality rate,Observation,outcome_20
447,NCT04425863,Patients Needing Drug Dose Adjustment,O1:135|O2:12|O3:20,O1:0|O2:0|O3:0,Mild Cases|Moderate Cases|Severe Cases,Drug Dose Adjustment ,Drug Dose Adjustment ,['Drug Dose Adjustment'],Time Frame: Day 1 through Day 29 ,4259634,Adjustment,Observation,outcome_355
448,NCT04425863,Adverse Events,O1:135|O2:12|O3:20,O1:0|O2:0|O3:1,Mild Cases|Moderate Cases|Severe Cases,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
449,NCT04542226,Clinical Status of the Patient (According to 7-point Ordinal Scale),O1:81,O1:0|O1:0|O1:22|O1:24|O1:24|O1:11|O1:0|O1:3|O1:27|O1:37|O1:9|O1:3|O1:2|O1:0,Adult Patients Hospitalized With COVID-19,ordinal scale,Ordinal Scale,"['Ordinal Scale', 'Clinical Status', 'ordinal scale']",Time Frame: Assessed on study day 15 ,4138597,Clinical status,Observation,outcome_356
450,NCT04542226,Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score,O1:80,O1:13.77,Adult Patients Hospitalized With COVID-19,"ordinal scale, Improvement",Ordinal Scale,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'ordinal scale']",Time Frame: assessed on study day 8 ,4138597,Clinical status,Observation,outcome_357
451,NCT04542226,Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale)),O1:80,O1:8.85,Adult Patients Hospitalized With COVID-19,Clinical Status ,Clinical Status ,['Clinical Status'],Time Frame: Baseline ,44813819,Assessment using Royal College of Physicians NEWS (national early warning score),Procedure,outcome_358
452,NCT04542226,Number of Patients Requiring Supplementary Oxygen,O1:81,O1:59|O1:22|O1:58|O1:23|O1:56|O1:25|O1:47|O1:34|O1:31|O1:50|O1:14|O1:67|O1:1|O1:80,Adult Patients Hospitalized With COVID-19,Oxygen,Oxygen,['Oxygen'],Time Frame: 28 days after randomization ,36308581,Supplemental oxygen,Meas Value,outcome_359
453,NCT04542226,Hospitalisation Duration,O1:80,O1:19.13,Adult Patients Hospitalized With COVID-19,Hospital,Hospitalization,['Hospital'],Time Frame: Day 15 ,46236995,Hospital stay duration,Observation,outcome_360
454,NCT04542226,Mortality,O1:81,O1:81|O1:0,Adult Patients Hospitalized With COVID-19,Mortality,Death ,['Mortality'],Time Frame: Up to and including day 7 ,4249566,Mortality rate,Observation,outcome_361
455,NCT04542226,The Number of Participants With Serious Adverse Events,O1:81,O1:1,Adult Patients Hospitalized With COVID-19,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
456,NCT04542226,The Number of Participants With Adverse Events,O1:81,O1:7,Adult Patients Hospitalized With COVID-19,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
457,NCT04542226,Number of Participants With Discontinuation of Drug Administration,O1:81,O1:1|O1:2,Adult Patients Hospitalized With COVID-19,Discontinuation of Drug Administration ,Discontinued,['Discontinuation of Drug Administration'],Time Frame: Day 1 through Day 10 ,4082382,Management of drug regimen,Procedure,outcome_362
458,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,4254482,APTT - reference,Measurement,outcome_363
459,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,4254482,APTT - reference,Measurement,outcome_363
460,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,['Activated Partial Thromboplastin Time (aPTT)'],Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,4254482,APTT - reference,Measurement,outcome_363
461,NCT04490239,"Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15",O1:6,O1:6|O1:0,Experimental Arm,Activated Partial Thromboplastin Time (aPTT),aPTT,['Activated Partial Thromboplastin Time (aPTT)'],"Time Frame: End-of treatment, Day 7 or 8 ",4254482,APTT - reference,Measurement,outcome_364
462,NCT04490239,Percent Change in Platelet Count From Pre-dose Baseline,O1:6,O1:2.2,Experimental Arm,Platelet,Platelet,['Platelet'],"Time Frame: From date of first admission to intensive care unit until discharge/transfer out of the ICU or date of death from any cause, whichever came first, assessed up to 6 months ",37397896,Percentage reticulated platelet count,Measurement,outcome_365
463,NCT04490239,"Number of Incidents of Epistaxis, Acute Phase",O1:6,O1:0,Experimental Arm,Incidents of Epistaxis,Incidents of Epistaxis,['Incidents of Epistaxis'],Time Frame: Day 12 ,4096682,Bleeding from nose,Condition,outcome_366
464,NCT04490239,"Number of Incidents of Epistaxis, Chronic Phase",O1:6,O1:1,Experimental Arm,Incidents of Epistaxis,Incidents of Epistaxis,['Incidents of Epistaxis'],NA,4262407,Control of hemorrhage of nose,Procedure,outcome_367
465,NCT04490239,"Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14",O1:6,O1:6|O1:0,Experimental Arm,Platelet,Platelet,['Platelet'],"Time Frame: From date of hospital admission until discharge from acute care hospital or date of death from any cause, whichever came first, assessed up to 6 months ",4306266,Platelet count abnormal,Condition,outcome_368
466,NCT04490239,"Other Adverse Effects, Acute Phase",O1:6,O1:2,Experimental Arm,Effect,Effect,"['Effect', 'Adverse']",Time Frame: Day 1 through Day 29 ,4105886,Adverse reaction,Condition,outcome_369
467,NCT04490239,"Other Adverse Effects, Chronic Phase",O1:6,O1:5,Experimental Arm,Effect,Effect,"['Effect', 'Adverse']",Time Frame: Day 1 through Day 29 ,4105886,Adverse reaction,Condition,outcome_369
468,NCT04327388,Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points,O1:159|O2:173|O3:84,O1:10.0|O2:10.0|O3:12.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'scale score', 'ordinal scale']",Time Frame: Day 14 ,4138597,Clinical status,Observation,outcome_218
469,NCT04327388,Percentage of Participants Who Were Alive at Day 29,O1:159|O2:173|O3:84,O1:89.9|O2:91.9|O3:91.7,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Alive,Alive,['Alive'],Time Frame: From starting to the end of ivermectin therapy (0 to the end of 5th day) ,44804077,Survival rate,Observation,outcome_370
470,NCT04327388,"Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29",O1:159|O2:173|O3:84,O1:25.2|O2:25.4|O3:23.8|O1:51.6|O2:48.6|O3:42.9|O1:74.8|O2:76.9|O3:71.4|O1:80.5|O2:81.5|O3:85.7|O1:84.9|O2:84.4|O3:88.1,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,"['Ordinal Scale', 'improvement', 'Improvement', 'Clinical Status', 'scale score', 'ordinal scale']",Time Frame: 4 weeks ,4138597,Clinical status,Observation,outcome_371
471,NCT04327388,"Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score",O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:158|O2:171|O3:83|O1:155|O2:169|O3:83|O1:156|O2:170|O3:83,O1:0.1|O2:0.1|O3:0.2|O1:0.7|O2:0.7|O3:0.7|O1:1.9|O2:2.0|O3:1.7|O1:2.3|O2:2.3|O3:2.5|O1:2.5|O2:2.5|O3:2.7,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,ordinal scale,Ordinal Scale,"['Ordinal Scale', 'scale score', 'ordinal scale']",Time Frame: 30 days ,4062806,Scale,Device,outcome_372
472,NCT04327388,Time to Resolution of Fever,O1:159|O2:173|O3:84,O1:8.0|O2:9.0|O3:7.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",21495022,Fever duration,Observation,outcome_65
473,NCT04327388,Time to Resolution of Fever and Improvement in Oxygenation,O1:159|O2:173|O3:84,O1:9.0|O2:10.0|O3:8.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,"['Oxygen', 'improvement', 'Improvement', 'Fever']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",21495022,Fever duration,Observation,outcome_65
474,NCT04327388,Number of Days With Fever,O1:143|O2:159|O3:77,O1:1.2|O2:1.3|O3:1.8,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Fever ,Fever ,['Fever'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",21495022,Fever duration,Observation,outcome_65
475,NCT04327388,"Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29",O1:159|O2:169|O3:84|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:146|O2:163|O3:79|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:159|O2:169|O3:84|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:135|O2:143|O3:74|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:61|O2:67|O3:36|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:29|O2:38|O3:12|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5|O1:14|O2:18|O3:5,O1:28.8|O2:22.1|O3:34.2|O1:0|O2:0|O3:0|O1:34.2|O2:37.4|O3:27.8|O1:37.0|O2:40.5|O3:38.0|O1:52.8|O2:56.2|O3:40.5|O1:0.6|O2:1.2|O3:0|O1:19.5|O2:16.6|O3:28.6|O1:27.0|O2:26.0|O3:31.0|O1:57.0|O2:60.8|O3:51.4|O1:0|O2:2.1|O3:0|O1:20.0|O2:10.5|O3:20.3|O1:23.0|O2:26.6|O3:28.4|O1:52.5|O2:52.2|O3:61.1|O1:0|O2:1.5|O3:2.8|O1:21.3|O2:19.4|O3:13.9|O1:26.2|O2:26.9|O3:22.2|O1:44.8|O2:50.0|O3:66.7|O1:13.8|O2:0|O3:0|O1:24.1|O2:21.1|O3:8.3|O1:17.2|O2:28.9|O3:25.0|O1:57.1|O2:27.8|O3:60.0|O1:0|O2:0|O3:0|O1:14.3|O2:27.8|O3:20.0|O1:28.6|O2:44.4|O3:20.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Clinical Risk,Clinical Risk,"['Clinical Risk', 'National Early Warning Score 2']",Time Frame: Baseline ,37208353,Royal College of Physicians NEWS2 (National Early Warning Score 2) total score,Measurement,outcome_373
476,NCT04327388,Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours,O1:159|O2:173|O3:84,O1:9.0|O2:9.0|O3:11.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Time to National Early Warning Score,Time to National Early Warning Score,['Time to National Early Warning Score'],Time Frame: 14 days ,44808684,Royal College of Physicians NEWS (national early warning score),Measurement,outcome_374
477,NCT04327388,"Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2",O1:146|O2:159|O3:79|O1:146|O2:159|O3:79|O1:122|O2:133|O3:69|O1:55|O2:62|O3:33|O1:26|O2:34|O3:12|O1:13|O2:17|O3:5,O1:-1.07|O2:-1.25|O3:-0.36|O1:-1.63|O2:-1.47|O3:-0.83|O1:-2.10|O2:-1.83|O3:-2.36|O1:-3.02|O2:-2.24|O3:-2.96|O1:-2.57|O2:-1.27|O3:-3.64,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,National Early Warning Score 2 ,National Early Warning Score 2 ,['National Early Warning Score 2'],Time Frame: Up to 28 days ,44808684,Royal College of Physicians NEWS (national early warning score),Measurement,outcome_375
478,NCT04327388,Time-to-improvement in Oxygenation,O1:159|O2:173|O3:84,O1:6.0|O2:6.0|O3:7.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,improvement,Improvement,"['Oxygen', 'improvement', 'Improvement']",Time Frame: 4 week ,19025274|4308350,oxygen|Improvement of status,Drug|Observation,outcome_376
479,NCT04327388,Percentage of Participants Alive Off Supplemental Oxygen at Day 29,O1:159|O2:173|O3:84,O1:84.9|O2:83.8|O3:86.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen,Oxygen,"['Oxygen', 'Alive']",Time Frame: 28 days after randomization ,36310094,No supplemental oxygen,Meas Value,outcome_328
480,NCT04327388,Percentage of Days With Hypoxemia,O1:159|O2:173|O3:84,O1:73.01|O2:75.10|O3:76.32,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hypoxemia ,Hypoxemia ,['Hypoxemia'],"Time Frame: By Visit 3, approximately 10 days ",437390,Hypoxemia,Condition,outcome_377
481,NCT04327388,Percentage of Days With Supplemental Oxygen Use,O1:159|O2:173|O3:84,O1:70.57|O2:73.30|O3:73.23,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen Use,Oxygen,"['Oxygen', 'Oxygen Use']",Time Frame: 28 days after randomization ,36304401,Use of supplemental oxygen,Observation,outcome_378
482,NCT04327388,Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute,O1:150|O2:164|O3:78,O1:14.74|O2:14.58|O3:15.74,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Respiratory Rate,Respiratory Rate,['Respiratory Rate'],Time Frame: Baseline to Day 29 ,4193574,Respiratory percentage,Measurement,outcome_379
483,NCT04327388,Time to Oxygen Saturation >= 94% on Room Air,O1:159|O2:173|O3:84,O1:8.0|O2:8.0|O3:8.0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Oxygen,Oxygen,"['Oxygen', 'Oxygen Saturation']",Time Frame: 28 days after randomization ,36685445,Arterial oxygen saturation on room air at rest,Measurement,outcome_380
484,NCT04327388,Mean Number of Ventilator Free Days,O1:159|O2:173|O3:84,O1:23.8|O2:24.0|O3:24.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Ventilator Free,Ventilator Free,['Ventilator Free'],Time Frame: Pre-SSI only ,44786857,Days on ventilator,Measurement,outcome_381
485,NCT04327388,"Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula",O1:127|O2:141|O3:68,O1:20.5|O2:23.4|O3:19.1,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Baseline, Days 3, 5, 8, 11, 15, and 29 ",4177224,Noninvasive ventilation,Procedure,outcome_382
486,NCT04327388,Percentage of Participants Who Required Rescue Medication,O1:159|O2:173|O3:84,O1:13.8|O2:15.0|O3:22.6,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Rescue Medication ,Rescue Medication ,['Rescue Medication'],Time Frame: Baseline to Day 29 ,42535850,Has supply of rescue medication,Observation,outcome_383
487,NCT04327388,Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study,O1:98|O2:114|O3:56,O1:11.2|O2:14.9|O3:12.5,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Intensive Care,Intensive Care,"['Intensive Care', 'ICU']",Time Frame: Assessed for up to 28 days ,36311219,Intensive care unit (ICU),Meas Value,outcome_384
488,NCT04327388,Number of Days of Hospitalization Among Survivors (Alive Participants),O1:142|O2:155|O3:75,O1:15.6|O2:16.1|O3:15.9,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hospitalization,Hospitalization,"['Hospitalization', 'Alive', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 ,46236995,Hospital stay duration,Observation,outcome_22
489,NCT04327388,Number of Participants With Treatment-emergent Serious Adverse Events (SAEs),O1:159|O2:173|O3:84,O1:42|O2:51|O3:20,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Adverse Events,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",Time Frame: At the first day of the study ,45884383,Adverse event,Meas Value,outcome_12
490,NCT04327388,Number of Participants With Major or Opportunistic Bacterial or Fungal Infections,O1:159|O2:173|O3:84,O1:8|O2:15|O3:3,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Infect,Infect,['Infect'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) ",45885195,Infection,Meas Value,outcome_385
491,NCT04327388,Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection,O1:159|O2:173|O3:84|O1:159|O2:173|O3:84|O1:3|O2:6|O3:0,O1:3|O2:6|O3:0|O1:0|O2:0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Infect,Infect,['Infect'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) ",320073,Neutropenia,Condition,outcome_386
492,NCT04327388,"Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation",O1:159|O2:173|O3:84,O1:1|O2:6|O3:0|O1:1|O2:7|O3:0|O1:1|O2:0|O3:0,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Gastrointestinal Perforation ,Gastrointestinal Perforation ,['Gastrointestinal Perforation'],"Time Frame: Baseline, Minutes 5, 10, 15, 30 (15 minutes after treatment ends) ",42536536,Gastrointestinal hypersensitivity caused by food,Condition,outcome_387
493,NCT04327388,"Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets",O1:156|O2:170|O3:84,O1:29|O2:34|O3:15|O1:0|O2:0|O3:0|O1:32|O2:30|O3:15|O1:19|O2:31|O3:1|O1:13|O2:21|O3:6|O1:2|O2:7|O3:3|O1:3|O2:2|O3:2,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Hemoglobin,Hemoglobin,"['Platelets', 'Platelet', 'Hemoglobin']",Time Frame: Day 1 through Day 14 ,45878745,Abnormal,Meas Value,outcome_388
494,NCT04327388,Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters,O1:156|O2:170|O3:84,O1:15|O2:15|O3:5|O1:31|O2:30|O3:10|O1:6|O2:7|O3:3,Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Renal Function Parameters ,Renal Function Parameters ,['Renal Function Parameters'],Time Frame: Baseline to Day 29 ,40282772,Renal function,Observation,outcome_389
495,NCT04327388,Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters,O1:156|O2:169|O3:84|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:168|O3:83|O1:156|O2:169|O3:84|O1:156|O2:169|O3:84,O1:60|O2:63|O3:24|O1:28|O2:25|O3:12|O1:6|O2:5|O3:3|O1:1|O2:0|O3:0|O1:5|O2:4|O3:4|O1:4|O2:2|O3:2,Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo|Sarilumab 200 mg|Sarilumab 400 mg|Placebo,Liver Function Parameters,Liver Function Parameters,['Liver Function Parameters'],Require Mechanical Ventilation,438878,Liver function tests abnormal,Condition,outcome_390
496,NCT04322396,Number of Days Alive and Discharged From Hospital Within 14 Days,O1:56|O2:61,O1:9|O2:9,Control|Intervention,discharge,Discharge,"['discharge', 'Discharge', 'Alive', 'Hospital']",NA,4084843,Discharged from hospital,Observation,outcome_391
497,NCT04322396,Categorization of Hospitalization Status,O1:56|O2:61,O1:2|O2:1|O1:1|O2:3|O1:0|O2:1|O1:2|O2:2|O1:2|O2:1|O1:0|O2:1|O1:27|O2:26|O1:22|O2:26,Control|Intervention,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,45884746,Hospitalization,Meas Value,outcome_143
498,NCT04322396,Length of Stay in ICU,O1:56|O2:61,O1:11|O2:14,Control|Intervention,ICU,ICU,"['Length of Stay', 'ICU']",NA,44786856,Days in intensive care unit,Observation,outcome_181
499,NCT04322396,Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization,O1:56|O2:61,O1:1|O2:3,Control|Intervention,Non-invasive Ventilation (NIV) ,NIV,"['Hospitalization', 'hospitalization', 'Hospital']",NA,4177224,Noninvasive ventilation,Procedure,outcome_392
500,NCT04322396,Mortality,O1:56|O2:61,O1:2|O2:1,Control|Intervention,Mortality,Death ,['Mortality'],NA,4249566,Mortality rate,Observation,outcome_137
501,NCT04322396,Length of Hospitalization,O1:56|O2:61,O1:4|O2:4,Control|Intervention,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",NA,46236995,Hospital stay duration,Observation,outcome_300
502,NCT04322396,Days Alive and Discharged From Hospital,O1:56|O2:61,O1:26|O2:26,Control|Intervention,discharge,Discharge,"['discharge', 'Discharge', 'Alive', 'Hospital']",NA,4084843,Discharged from hospital,Observation,outcome_391
503,NCT04322396,Number of Readmissions (All Causes),O1:56|O2:61,O1:6|O2:9,Control|Intervention,Readmissions,Readmissions,[],NA,36210471,Readmission,Meas Value,outcome_393
504,NCT04322396,Number of Days Using Non-invasive Ventilation (NIV),O1:1|O2:3,O1:9.0|O2:6.7,Control|Intervention,Non-invasive Ventilation (NIV),NIV,[],NA,4177224,Noninvasive ventilation,Procedure,outcome_392
505,NCT04322396,Change in Patient's Oxygen Partial Pressure,O1:56|O2:61,O1:-0.2|O2:-3.0,Control|Intervention,Oxygen,Oxygen,['Oxygen'],NA,3013702,Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood,Measurement,outcome_394
506,NCT04322396,Change in Patient's Carbondioxide Partial Pressure,O1:56|O2:61,O1:1.4|O2:-3.0,Control|Intervention,Pressure,Pressure,[],NA,3033203,Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood,Measurement,outcome_395
507,NCT04322396,Change of pH in Blood,O1:56|O2:61,O1:0.0|O2:0.0,Control|Intervention,PH,PH,[],NA,3010421,pH of Blood,Measurement,outcome_396
508,NCT04322396,"Time for no Oxygen Supplement (or Regular Oxygen Supplement ""LTOT"")",O1:27|O2:25,O1:72|O2:72,Control|Intervention,Oxygen,Oxygen,['Oxygen'],NA,36310094,No supplemental oxygen,Meas Value,outcome_397
509,NCT04308668,Number of Participants With Active COVID-19 Disease at Day 14 Among Those Who Were Asymptomatic at Baseline,O1:414|O2:407,O1:49|O2:58,Treatment|Placebo,Active COVID-19 Disease at Day 14,Active COVID-19 Disease at Day 15,"['Active COVID-19 Disease at Day 14', 'Symptom']",Time Frame: Treatment period of 7 days (Day 1 to Day 8) ,3662381,Asymptomatic SARS-CoV-2,Condition,outcome_398
510,NCT04308668,Change in Disease Severity Over 14 Days Among Those Who Are Symptomatic at Baseline,O1:212|O2:211,O1:-2.6|O2:-2.33,Treatment|Placebo,Disease Severity,Disease Severity,"['Symptom', 'Disease Severity']",Time Frame: Day 1 through Day 29 ,45877040,Symptomatic,Meas Value,outcome_399
511,NCT04308668,Rate of Hospitalization,O1:645|O2:641,O1:5|O2:9,Treatment|Placebo,Hospitalization,Hospitalization,"['Hospitalization', 'hospitalization', 'Hospital']",Time Frame: Day 1 through Day 29 ,45884746,Hospitalization,Meas Value,outcome_400
512,NCT04308668,Rate of Death,O1:645|O2:641,O1:1|O2:1,Treatment|Placebo,Death ,Death ,['Death'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4249566,Mortality rate,Observation,outcome_401
513,NCT04308668,Rate of Confirmed SARS-CoV-2 Detection,O1:414|O2:407,O1:11|O2:9,Treatment|Placebo,Detection ,Detection ,['Detection'],"Time Frame: Days 1, 3, 5, 8, 11, 15, 22, and 29 ",3655885,SARS-CoV-2 IgM,Observation,outcome_402
514,NCT04308668,Occurrence of Symptoms Compatible With COVID-19 (Possible Disease),O1:414|O2:407,O1:48|O2:55,Treatment|Placebo,Occurrence of Symptoms,Symptoms,"['Symptom', 'Occurrence of Symptoms']","Time Frame: Day 7, Day 14, Day 21 & Day 30 ",1333343,COVID-19 Related Symptoms,Observation,outcome_403
515,NCT04308668,Rate of All-Cause Study Medicine Discontinuation or Withdrawal,O1:645|O2:641,O1:97|O2:63,Treatment|Placebo,Medicine Discontinuation,Medicine Discontinuation,['Medicine Discontinuation'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 60 days ",4164526,Medication discontinued,Observation,outcome_404
516,NCT04308668,Overall Symptom Severity at 5 and 14 Days,O1:212|O2:211,O1:-2.22|O2:-2.05|O1:-3.36|O2:-3.08,Treatment|Placebo,Symptom Severity,Symptom,"['Symptom Severity', 'Symptom']",Time Frame: 14 days ,4037113,Symptom severity,Observation,outcome_405
517,NCT04308668,Number of Participants With Severe COVID-19 Disease at 14 Days Among Those Who Are Symptomatic at Trial Entry,O1:231|O2:234,O1:5|O2:8,Treatment|Placebo,Severe COVID-19 Disease at 14 Days,COVID-19,"['Symptom', 'Severe COVID-19 Disease at 14 Days']",Time Frame: 7 days ,37311061,COVID-19,Condition,outcome_406
518,NCT04340557,Mechanical Ventilation,O1:16|O2:15,O1:1|O2:1,Group A (Study Drug+SOC)|Group B (SOC),Mechanical Ventilation,Mechanical Ventilation,"['mechanical Ventilation', 'Mechanical Ventilation']","Time Frame: Day 15, Day 29 ",4230167,Artificial respiration,Procedure,outcome_407
519,NCT04340557,ICU Transfer,O1:16|O2:15,O1:1|O2:2,Group A (Study Drug+SOC)|Group B (SOC),ICU,ICU,['ICU'],Time Frame: 28 days ,4265599,Patient transfer to intensive care unit,Observation,outcome_408
520,NCT04340557,Oxygen Therapy,O1:16|O2:15,"O1:10,469|O2:82,734",Group A (Study Drug+SOC)|Group B (SOC),Oxygen,Oxygen,"['Oxygen', 'Oxygen Therapy']",Time Frame: 28 days after randomization ,36311244,Oxygen therapy,Meas Value,outcome_253
521,NCT04392219,Part 1: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events,O1:16|O2:6|O3:6|O4:6|O5:6|O6:6|O7:6|O8:6|O9:6,O1:7|O2:2|O3:0|O4:3|O5:3|O6:4|O7:2|O8:1|O9:2|O1:7|O2:2|O3:0|O4:3|O5:3|O6:4|O7:2|O8:1|O9:2|O1:1|O2:0|O3:0|O4:0|O5:1|O6:0|O7:0|O8:0|O9:0|O1:0|O2:0|O3:0|O4:0|O5:0|O6:0|O7:0|O8:0|O9:0,Part 1 - Placebo|Part 1 - 50 mg EIDD-2801|Part 1 - 100 mg EIDD-2801|Part 1 - 200 mg EIDD-2801|Part 1 - 400 mg EIDD-2801|Part 1 - 600 mg EIDD-2801|Part 1 - 800 mg EIDD-2801|Part 1 - 1200 mg EIDD-2801|Part 1 - 1600 mg EIDD-2801,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,45884383,Adverse event,Meas Value,outcome_199
522,NCT04392219,Part 3: Number of Participants With Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events,O1:14|O2:6|O3:6|O4:6|O5:6|O6:6|O7:6|O8:6,O1:7|O2:2|O3:3|O4:3|O5:2|O6:3|O7:2|O8:3|O1:7|O2:2|O3:3|O4:3|O5:2|O6:3|O7:2|O8:3|O1:0|O2:0|O3:0|O4:1|O5:0|O6:0|O7:0|O8:0|O1:0|O2:0|O3:0|O4:0|O5:0|O6:0|O7:0|O8:0,Part 3 - Placebo|Part 3 - 50 mg EIDD-2801|Part 3 - 100 mg EIDD-2801|Part 3 - 200 mg EIDD-2801|Part 3 - 300 mg EIDD-2801|Part 3 - 400 mg EIDD-2801|Part 3 - 600 mg EIDD-2801|Part 3 - 800 mg EIDD-2801,Adverse,Adverse,"['Adverse Events', 'Adverse', 'Adverse Event']",NA,45884383,Adverse event,Meas Value,outcome_199
523,NCT04634903,Change in Adolescent Depressive Symptom Severity,O1:818|O2:821|O3:813,O1:14.31|O2:14.15|O3:14.22|O1:12.57|O2:11.47|O3:11.58,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Depressive,Depressive,"['Symptom Severity', 'Depressive', 'Symptom']","Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",4037113,Symptom severity,Observation,outcome_409
524,NCT04634903,Change in State Hope Scale - Pathways Subscale,O1:818|O2:821|O3:813,O1:3.88|O2:3.93|O3:3.96|O1:5.26|O2:5.68|O3:5.50|O1:4.89|O2:5.06|O3:5.17,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),State Hope Scale - Pathways Subscale ,Scale,['State Hope Scale - Pathways Subscale'],Time Frame: Days 1 - 29. ,4085051|4080388,Level of hope|Scale - rank,Observation|Observation,outcome_410
525,NCT04634903,Change in Beck Hopelessness Scale - 4 Item Version,O1:818|O2:821|O3:813,O1:1.71|O2:1.72|O3:1.72|O1:1.36|O2:1.22|O3:1.21|O1:1.51|O2:1.37|O3:1.39,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Beck Hopelessness Scale - 4 Item Version ,Beck Hopelessness Scale - 5 Item Version,['Beck Hopelessness Scale - 4 Item Version'],Time Frame: At the end of 10th day ,4128243,Beck hopelessness scale,Measurement,outcome_411
526,NCT04634903,Program Feedback Scale,O1:630|O2:729|O3:653,O1:3.80|O2:3.93|O3:3.83|O1:4.54|O2:4.46|O3:4.48|O1:4.46|O2:4.42|O3:4.48|O1:4.45|O2:4.42|O3:4.45|O1:3.97|O2:4.12|O3:3.93|O1:4.24|O2:4.30|O3:4.20|O1:4.50|O2:4.54|O3:4.47,Supportive Therapy SSI (ST-SSI)|Behavioral Activation SSI (BA-SSI)|Growth Mindset SSI (GM-SSI),Program Feedback Scale ,Scale,['Program Feedback Scale'],Time Frame: 14 days ,36662336,Feedback system,Meas Value,outcome_412
527,NCT04160975,Rating of Sender,O1:832|O2:430|O3:827|O4:845,O1:.1828917|O2:-.0750636|O3:.0997998|O4:-.5397662,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Sender,Sender,[],NA,42050594,Send,Geography,outcome_413
528,NCT04160975,Rating of Signal,O1:832|O2:1221|O3:827|O4:845,O1:.1387205|O2:-.0088105|O3:.1423725|O4:-.0806321,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Signal,Signal,[],NA,4217210,Sign,Condition,outcome_414
529,NCT04160975,Signal Content Recall,O1:832|O2:1221|O3:827|O4:845,O1:-.0062555|O2:.0193832|O3:.0041984|O4:.1166304,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Signal,Signal,[],NA,4217210,Sign,Condition,outcome_414
530,NCT04160975,Safety Beliefs,O1:832|O2:1221|O3:827|O4:845,O1:-.0979564|O2:-.027714|O3:-.1065867|O4:-.0242752,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Safety,Safety,[],NA,45880179,Safety,Meas Value,outcome_415
531,NCT04160975,Coupon Interest,O1:832|O2:1221|O3:827|O4:845,O1:-.0078177|O2:-.0827849|O3:.0280955|O4:-.0162865,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Coupon Interest,Coupon Interest,[],NA,45877292,Interested,Meas Value,outcome_416
532,NCT04160975,(Posterior) Flu Vaccine Intent,O1:832|O2:1221|O3:827|O4:845,O1:.0263281|O2:.0034755|O3:.0268659|O4:.0187403,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,[],NA,40761232,Date of influenza vaccination,Observation,outcome_417
533,NCT04160975,COVID-19 Vaccine Intent,O1:587|O2:866|O3:581|O4:592,O1:.0350147|O2:.009072|O3:.0544277|O4:.0881949,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,[],NA,1616924,Accepted or will accept COVID-19 vaccination once offered,Observation,outcome_418
534,NCT04160975,Flu Vaccine Take-up,O1:139|O2:377|O3:137|O4:151,O1:-7.70997|O2:-01.39307|O3:-12.00413|O4:14.96955,Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - Black Participants|Concordant (Arm A) vs. Discordant Expert Sender (Arm B) - White Participants|Acknowledgement (Arm A) vs. Standard Signal (Arm B) - Black Participants|Layperson Sender (Arm A) vs. Expert Sender (Arm B) - Black Participants,Vaccine,Vaccine,[],NA,42872395,Influenza vaccine needed,Observation,outcome_419
535,NCT04406194,AUC0-tlast of Favipiravir,O1:29|O2:29,O1:9641.989|O2:9907.170,Favicovir 200 mg FT|Avigan 200 mg FT,AUC0-tlast of Favipiravir ,AUC1-tlast of Favipiravir,"['AUC0-tlast', 'AUC0-tlast of Favipiravir']",Time Frame: From 6th to the end of 10th day ,32765,Favipiravir,Drug,outcome_420
536,NCT04406194,Cmax of Favipiravir,O1:29|O2:29,O1:5411.624|O2:5002.171,Favicovir 200 mg FT|Avigan 200 mg FT,Cmax of Favipiravir ,Favipiravir Cmax ,['Cmax of Favipiravir'],Time Frame: Baseline ,32765,Favipiravir,Drug,outcome_421
537,NCT04406194,AUC0-inf of Favipiravir,O1:29|O2:29,O1:9910.494|O2:10152.115,Favicovir 200 mg FT|Avigan 200 mg FT,AUC0-inf of Favipiravir ,AUC0-inf of Favipiravir ,['AUC0-inf of Favipiravir'],Time Frame: From 6th to the end of 10th day ,32765,Favipiravir,Drug,outcome_422
538,NCT04406194,Tmax of Favipiravir,O1:29|O2:29,O1:0.609|O2:0.733,Favicovir 200 mg FT|Avigan 200 mg FT,Tmax of Favipiravir ,Favipiravir Cmax ,['Tmax of Favipiravir'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",32765,Favipiravir,Drug,outcome_423
539,NCT04400682,AUC0-tlast,O1:25|O2:25,O1:10400.038|O2:9907.948,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),AUC0-tlast ,AUC1-tlast,['AUC0-tlast'],Time Frame: From 6th to the end of 10th day ,4086150,Parameter,Observation,outcome_424
540,NCT04400682,Favipiravir Cmax,O1:25|O2:25,O1:5242.459|O2:4969.881,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),Favipiravir Cmax ,Favipiravir Cmax ,['Favipiravir Cmax'],"Time Frame: Days 1, 3, 5, 8, 11, 15 and 29 ",32765,Favipiravir,Drug,outcome_425
541,NCT04400682,AUC0-inf of Favipiravir,O1:25|O2:25,O1:10400.038|O2:10186.389,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),AUC0-inf of Favipiravir ,AUC0-inf of Favipiravir ,['AUC0-inf of Favipiravir'],Time Frame: From 6th to the end of 10th day ,32765,Favipiravir,Drug,outcome_422
542,NCT04400682,Tmax of Favipiravir,O1:25|O2:25,O1:0.766|O2:0.770,FAVIRA (Novelfarma-Turkey)|AVIGAN (Toyama-Japan),Tmax of Favipiravir ,Favipiravir Cmax ,['Tmax of Favipiravir'],"Time Frame: from date of patient admission to date of patient discharge or date of death, whichever came first, assessed up to 45 days ",32765,Favipiravir,Drug,outcome_423
